Menu
 
Research menu
Jump to menu

Publications:  Prof Graham Foster

Drysdale K, Ntuli Y, Bestwick J, Gelson W, Agarwal K, Forton D, Mutimer D, Elsharkawy AM et al.(2020). English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed. Aliment Pharmacol Ther vol. 52, (1) 168-181.
10.1111/apt.15780
Dore GJ, Feld JJ, Thompson A, Martinello M, Muir AJ, Agarwal K, Müllhaupt B, Wedemeyer H et al.(2020). Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol vol. 72, (3) 431-440.
10.1016/j.jhep.2019.10.010
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64482
Fawsitt CG, Vickerman P, Cooke GS, STOP HCV Consortium, Welton NJ(2020). Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus. Value Health vol. 23, (2) 180-190.
10.1016/j.jval.2019.08.012
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64480
Williams R, Aithal G, Alexander GJ, Allison M, Armstrong I, Aspinall R, Baker A, Batterham R et al.(2020). Unacceptable failures: the final report of the Lancet Commission into liver disease in the UK. Lancet vol. 395, (10219) 226-239.
10.1016/S0140-6736(19)32908-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64479
Marcellin P, Xie Q, Woon Paik S, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M et al.(2020). Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B. PLoS One vol. 15, (4)
10.1371/journal.pone.0230893
Bradshaw D, Mbisa JL, Geretti AM, Healy BJ, Cooke GS, Foster GR, Thomson EC, McLauchlan J et al.(2019). Consensus recommendations for resistance testing in the management of chronic hepatitis C virus infection: Public Health England HCV Resistance Group. J Infect vol. 79, (6) 503-512.
10.1016/j.jinf.2019.10.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64541
Ansari MA, Aranday-Cortes E, Ip CL, Da Silva Filipe A, Lau SH, Bamford C, Bonsall D, Trebes A et al.(2019). Interferon lambda 4 impacts the genetic diversity of hepatitis c virus. eLife vol. 8,
10.7554/eLife.42463
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64964
Wing PAC, Jones M, Cheung M, DaSilva S, Bamford C, Jason Lee WY, Aranday-Cortes E, Da Silva Filipe A et al.(2019). Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir. Gastroenterology vol. 157, (3) 692-704.e9.
10.1053/j.gastro.2019.05.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65203
Hickman M, Dillon JF, Elliott L, De Angelis D, Vickerman P, Foster G, Donnan P, Eriksen A et al.(2019). Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - A natural experiment (protocol). BMJ Open vol. 9, (9)
10.1136/bmjopen-2019-029538
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64955
Wei L, Pavlovic V, Bansal AT, Chen X, Foster GR, He H, Kao J-H, Lampertico P et al.(2019). Genetic variation in FCER1A predicts peginterferon alfa-2a-induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B. J Viral Hepat vol. 26, (9) 1040-1049.
10.1111/jvh.13107
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57732
Forrest EH, Storey N, Sinha R, Atkinson SR, Vergis N, Richardson P, Masson S, Ryder S et al.(2019). Baseline neutrophil-to-lymphocyte ratio predicts response to corticosteroids and is associated with infection and renal dysfunction in alcoholic hepatitis. Aliment Pharmacol Ther vol. 50, (4) 442-453.
10.1111/apt.15335
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64481
Naganuma A, Chayama K, Notsumata K, Gane E, Foster GR, Wyles D, Kwo P, Crown E et al.(2019). Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol vol. 54, (8) 752-761.
10.1007/s00535-019-01569-7
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58388
Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al.(2019). Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. Eurosurveillance vol. 24, (27)
10.2807/1560-7917.ES.2019.24.27.1800377
https://qmro.qmul.ac.uk/xmlui/handle/123456789/65019
Shokatpour N, Vaezjalali M, Foster GR, Sali S(2019). Nucleotide Substitutions in Hepatitis B Viruses Derived from Chronic HBV Patients. Mediterranean Journal of Hematology and Infectious Diseases vol. 11, (1) e2019046-e2019046.
10.4084/MJHID.2019.046
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64966
Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D et al.(2019). The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Alimentary Pharmacology and Therapeutics vol. 50, (2) 204-214.
10.1111/apt.15296
Harrison GI, Murray K, Gore R, Lee P, Sreedharan A, Richardson P, Hughes AJ, Wiselka M et al.(2019). The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. Addiction vol. 114, (6) 1113-1122.
10.1111/add.14569
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57641
Fawsitt CG, Vickerman P, Cooke G, Welton NJ, STOP-HCV Consortium(2019). A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. Value in Health vol. 22, (6) 693-703.
10.1016/j.jval.2018.12.011
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64995
Mecci J, Maxan M-E, Kemos P, Telfer P, Barroso F, Foster G, Banu K (2019). Diagnosis of sickle cell liver disease may be aided by non-invasive tests. JOURNAL OF HEPATOLOGY. vol. 70, E586-E587.
10.1016/S0618-8278(19)31174-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64896
Drysdale K, Townley C, Mahomed F, Foster G (2019). Effectiveness of therapy in 16, 567 directly-acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis. JOURNAL OF HEPATOLOGY. vol. 70, E131-E131.
10.1016/S0618-8278(19)30231-2
Stagg HR, Surey J, Francis M, MacLellan J, Foster GR, Charlett A, Abubakar I(2019). Improving engagement with healthcare in hepatitis C: A randomised controlled trial of a peer support intervention. BMC Medicine vol. 17, (1)
10.1186/s12916-019-1300-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57734
Russell A, Hepgul N, Nikkheslat N, Borsini A, Zajkowska Z, Moll N, Forton D, Agarwal K et al.(2019). Persistent fatigue induced by interferon-alpha: a novel, inflammation-based, proxy model of chronic fatigue syndrome. Psychoneuroendocrinology vol. 100, 276-285.
10.1016/j.psyneuen.2018.11.032
Lawitz E, Gane E, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich E, Katchman H et al.(2019). Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Journal of Viral Hepatitis vol. 26, (9) 1127-1138.
10.1111/jvh.13132
https://qmro.qmul.ac.uk/xmlui/handle/123456789/64907
Foster GR, Dore GJ, Wang S, Grebely J, Sherman KE, Baumgarten A, Conway B, Jackson D et al.(2019). Glecaprevir/pibrentasvir in patients with chronic HCV and recent drug use: An integrated analysis of 7 phase III studies. Drug and Alcohol Dependence vol. 194, 487-494.
10.1016/j.drugalcdep.2018.11.007
Foster GR, Asselah T, Kopecky-Bromberg S, Lei Y, Asatryan A, Trinh R, Zadeikis N, Mensa FJ(2019). Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older. PLoS One vol. 14, (1)
10.1371/journal.pone.0208506
https://qmro.qmul.ac.uk/xmlui/handle/123456789/57728
Williams R, Alexander G, Aspinall R, Batterham R, Bhala N, Bosanquet N, Severi K, Burton A et al.(2018). Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet vol. 392, (10162) 2398-2412.
10.1016/S0140-6736(18)32561-3
MADURASINGHE VW, ELDRIDGE S, GRIFFITHS C(2018). Case finding and therapy for chronic viral hepatitis in primary care (HepFREE): a cluster-randomised controlled trial. The Lancet Gastroenterology & Hepatology
10.1016/S2468-1253(18)30318-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/53530
Felizarta F, Asatryan A, Aguilar HI, Poordad F, Agarwal K, Nevens F, Hassanein TI, Foster GR et al. (2018). Durability of Sustained Virologic Response and Liver Safety in Patients Treated with Glecaprevir/Pibrentasvir: A Long-Term Follow-up Study. HEPATOLOGY. vol. 68, 358A-358A.
Buti M, Fung SK, Ahn SH, Foster GR, Yang JC, Wang H, Flaherty JF, Gaggar A et al. (2018). Loss of Hepatitis B e Antigen (HBeAg) during Nucleos(t)Ide (NUC) Therapy Is Associated with Greater Improvement in Liver Fibrosis. HEPATOLOGY. vol. 68, 1201A-1201A.
Roberts SK, Buti M, Foster GR, Luis Calleja J, Sood A, Isakov VA, Ola R, Weiland H et al. (2018). Sofosbuvir/Velpatasvir for Patients with Chronic Genotype 3 HCV Infection with Compensated Cirrhosis: An Integrated Analysis of Phase 2 and Phase 3 Clinical Trials. HEPATOLOGY. vol. 68, 373A-374A.
Heath H, Britton G, Kudo H, Renney G, Ward M, Goldin RD, Hutchins R, Foster GR et al. (2018). Stat2 Deletion Impairs MAPK Signaling, NF-Kb Localisation to the Nucleus, Cytokine Expression and Is Protective from Sterile Inflammation. HEPATOLOGY. vol. 68, 628A-628A.
Vinikoor MJ, Sinkala E, Kanunga A, Muchimba M, Nsokolo B, Chilengi R, Wandeler G, Mulenga J et al.(2018). Chronic hepatitis B virus monoinfection at a university hospital in Zambia. World J Hepatol vol. 10, (9) 622-628.
10.4254/wjh.v10.i9.622
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55920
Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS et al.(2018). High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1–6 patients without cirrhosis. Journal of Hepatology vol. 69, (2) 293-300.
10.1016/j.jhep.2018.03.007
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al.(2018). Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial. Hepatology vol. 67, (6) 2113-2126.
10.1002/hep.29852
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36723
Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C(2018). Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department-uncovering the iceberg?. Epidemiology and Infection vol. 146, (8) 1026-1035.
10.1017/S0950268818000870
Younossi ZM, Stepanova M, Asselah T, Foster G, Patel K, Bräu N, Swain M, Tran T et al.(2018). Hepatitis C in Patients with Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clinical Infectious Diseases vol. 66, (11) 1742-1750.
10.1093/cid/cix1106
Brown A, Hézode C, Zuckerman E, Foster GR, Zekry A, Roberts SK, Lahser F, Durkan C et al.(2018). Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. Journal of Viral Hepatitis vol. 25, (5) 457-464.
10.1111/jvh.12801
Dalgard O, Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Soyemi T et al. (2018). Sofosbuvir-Based Direct-Acting Antiviral Therapies for Hcv in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. HEROIN ADDICTION AND RELATED CLINICAL PROBLEMS. vol. 20, 13-14.
Bridge S, Pagano S, Jones M, Foster G, Neely D, Vuilleumier N, Bassendine M (2018). Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. JOURNAL OF HEPATOLOGY. vol. 68, S539-S540.
10.1016/S0168-8278(18)31335-7
Poordad F, Zeuzem S, Asatryan A, Foster G, Gane E, Wyles D, Stanislas P, Ferret MB et al. (2018). Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis. JOURNAL OF HEPATOLOGY. vol. 68, S262-S262.
10.1016/S0168-8278(18)30737-2
Flanagan S, Appleby VJ, Gaviria J, Kunkel J, Madurasinghe V, Eldridge S, Moreea S, Agarwal K et al. (2018). HepFree: Screening migrant patients for viral hepatitis in primary care. A 90,000 patient randomised controlled trial indicates benefits are most obvious in older patients. JOURNAL OF HEPATOLOGY. vol. 68, S51-S52.
10.1016/S0168-8278(18)30323-4
Cheung M, Mutimer D, Agarwal K, Brown A, Aldersley M, Foster G, Irving W (2018). Long term real life follow-up of patients with chronic hepatitis C virus and decompensated cirrhosis after direct acting antivirals - what is the clinical benefit of antiviral treatment?. JOURNAL OF HEPATOLOGY. vol. 68, S109-S110.
10.1016/S0168-8278(18)30436-7
De Silva S, Li W, Kemos P, Brindley JH, Mecci J, Samsuddin S, Chin-Aleong J, Feakins RM et al.(2018). Non-invasive markers of liver fibrosis in fatty liver disease are unreliable in people of south asian descent. Frontline Gastroenterology vol. 9, (2) 115-121.
10.1136/flgastro-2017-100865
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W et al.(2018). Reply to: "Reply to: 'Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries'". J Hepatol vol. 68, (4) 864-866.
10.1016/j.jhep.2017.11.044
https://qmro.qmul.ac.uk/xmlui/handle/123456789/37583
Heath H, Kudo H, Renney G, Ward M, Cutillas P, Goldin RD, Hutchins R, Foster G et al. (2018). The pathogenic role of Stat2 in inflammation is independent of canonical interferon signaling and is mediated by TNFa. JOURNAL OF HEPATOLOGY. vol. 68, S612-S612.
10.1016/S0168-8278(18)31480-6
Podlaha O, Agarwal K, Thompson A, Foster G, Samuel D, Yatsuhashi H, Gaggar A, Kitrinos K et al. (2018). Whole genome viral sequencing reveals subgenotype specific dynamics of antiviral treatment response in HBeAg positive and treatment naive chronic hepatitis B patients. JOURNAL OF HEPATOLOGY. vol. 68, S778-S779.
10.1016/S0168-8278(18)31824-5
Williams R, Alexander G, Armstrong I, Baker A, Bhala N, Camps-Walsh G, Cramp ME, de Lusignan S et al.(2018). Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: fourth report of the Lancet Standing Commission on Liver Disease in the UK. Lancet vol. 391, (10125) 1097-1107.
10.1016/S0140-6736(17)32866-0
Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J et al.(2018). Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1-6 and compensated cirrhosis or advanced fibrosis. Liver International vol. 38, (3) 443-450.
10.1111/liv.13534
Sinkala E, Zyambo K, Besa E, Kaonga P, Nsokolo B, Kayamba V, Vinikoor M, Zulu R et al.(2018). Rifaximin Reduces Markers of Inflammation and Bacterial 16S rRNA in Zambian Adults with Hepatosplenic Schistosomiasis: A Randomized Control Trial. Am J Trop Med Hyg
10.4269/ajtmh.17-0637
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55918
Bridge SH, Pagano S, Jones M, Foster GR, Neely D, Vuilleumier N, Bassendine MF(2018). Autoantibody to apolipoprotein A-1 in hepatitis C virus infection: a role in atherosclerosis?. Hepatol Int vol. 12, (1) 17-25.
10.1007/s12072-018-9842-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/38103
Shafran SD, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Pilot-Matias T, Pothacamury RK et al.(2018). Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III). Journal of Viral Hepatitis vol. 25, (2) 118-125.
10.1111/jvh.12782
Marshall AD, Cunningham EB, Nielsen S, Aghemo A, Alho H, Backmund M, Bruggmann P, Dalgard O et al. (2018). Restrictions for reimbursement of interferon-free direct-acting antiviral drugs for HCV infection in Europe. Lancet Gastroenterol Hepatol. vol. 3, 125-133.
10.1016/S2468-1253(17)30284-4
Grebely J, Feld JJ, Wyles D, Sulkowski M, Ni L, Llewellyn J, Mir HM, Sajed N et al.(2018). Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies. Open Forum Infect Dis vol. 5, (2)
10.1093/ofid/ofy001
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36234
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M et al.(2018). Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. New England Journal of Medicine vol. 378, (4) 354-369.
10.1056/NEJMoa1702417
https://qmro.qmul.ac.uk/xmlui/handle/123456789/32126
Nsokolo B, Kanunga A, Sinkala E, Zyambo K, Kumwenda D, Chama D, Muyinda G, Vinikoor M et al.(2018). Stage of disease in hepatitis B virus infection in Zambian adults is associated with large cell change but not well defined using classic biomarkers. Trans R Soc Trop Med Hyg vol. 111, (9) 425-432.
10.1093/trstmh/trx077
https://qmro.qmul.ac.uk/xmlui/handle/123456789/45143
KENNEDY P(2018). Hepatitis B virus–specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation. Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation vol. 128, (2) 668-681.
10.1172/JCI92812
https://qmro.qmul.ac.uk/xmlui/handle/123456789/55629
Grebely J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E et al.(2018). Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in patients with chronic hepatitis C virus genotype 1 infection receiving opioid substitution therapy: A post hoc analysis of 12 clinical trials. Open Forum Infectious Diseases vol. 5, (11)
10.1093/ofid/ofy248
https://qmro.qmul.ac.uk/xmlui/handle/123456789/56047
Foster GR, Wing P, Jones M, Lee W-YJ, Cheung MC, McLauchlan J, daSilva-Filipe A, Irving W et al. (2017). Polymorphisms in the genotype 3 hepatitis C virus polymerase protein modify the response to interferon and sofosbuvir. HEPATOLOGY. vol. 66, 1270A-1270A.
da Silva Filipe A, Sreenu V, Hughes J, Aranday-Cortes E, Irving WL, Foster GR, Agarwal K, Rosenberg W et al.(2017). Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries. Journal of Hepatology vol. 67, (6) 1348-1350.
10.1016/j.jhep.2017.06.035
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben-Ari Z, Foster GR et al.(2017). Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials. The Lancet Gastroenterology and Hepatology vol. 2, (11) 805-813.
10.1016/S2468-1253(17)30159-0
Lawitz E, Gane EJ, Feld JJ, Buti M, Foster GR, Rabinovitz M, Burnevich EZ, Katchman H et al. (2017). C-BREEZE 2: Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent (DAA) Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Genotype (GT) 1, 2, 3, 4, or 6. HEPATOLOGY. vol. 66, 34A-35A.
McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E, McDonald S, Wilkes B, Hutchinson SJ et al.(2017). Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol vol. 46, (5) 1391-1391h.
10.1093/ije/dyw362
Flanagan S, Appleby VJ, Gaviria J, Madurasinghe V, Kunkel J, Eldridge S, Moreea S, Agarwal K et al. (2017). HepFree: A large cluster randomised controlled cross sectional trial to assess screening and treating first and second generation migrants from 'At Risk' countries with chronic viral hepatitis. HEPATOLOGY. vol. 66, 550A-551A.
Younossi ZM, Stepanova M, Asselah T, Foster GR, Patel K, Brau N, Swain MG, Tran TT et al. (2017). Hepatitis C (HCV) in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response (SVR) on Patient-Reported Outcomes (PROs). HEPATOLOGY. vol. 66, 526A-526A.
Bernstein DE, Foster G, Dylla D, Mauss S, Nelson D, Asselah T, Flamm S, Cooper C et al. (2017). Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir to Treat HCV Genotype 1-6 Infection in Patients Without Cirrhosis Including HIV Co-Infection. AMERICAN JOURNAL OF GASTROENTEROLOGY. vol. 112, S490-S490.
10.14309/00000434-201710001-00869
El-Sherif O, Pertinez H, Irving W, Penchala SD, McLauchlan J, Foster GR, Norris S, Else L et al. (2017). Population pharmacokinetic analysis of ledipasvir in patients with decompensated cirrhosis - results from the UK Expanded Access programme. HEPATOLOGY. vol. 66, 831A-832A.
Macken L, Verma S, Foster GR, McLauchlan J, Irving W, UK HCVR (2017). Safety and Efficacy of Direct Acting Antivirals: UK Real World Experience from a Large Well Characterised Predominantly Cirrhotic HCV Cohort. HEPATOLOGY. vol. 66, 592A-593A.
Foster GR, Kopecky-Bromberg S, Lei Y, Mensa FJ (2017). Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials. HEPATOLOGY. vol. 66, 640A-641A.
Foster GR, Grebely J, Sherman KE, Wang S, Dore GJ, Baumgarten A, Conway B, III JDF et al. (2017). Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1-6 and Recent Drug Use. HEPATOLOGY. vol. 66, 636A-637A.
Poordad F, Nelson DR, Feld JJ, Fried MW, Wedemeyer H, Larsen L, Cohen DE, Cohen E et al.(2017). Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. J Hepatol vol. 67, (4) 700-707.
10.1016/j.jhep.2017.06.011
Puoti M, Foster G, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee S et al. (2017). High SVR Rates with 8 and 12 Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy and Safety Analysis of Genotype 1-6 Patients without Cirrhosis. SWISS MEDICAL WEEKLY. vol. 147, 20S-20S.
Midgard H, Hajarizadeh B, Cunningham EB, Conway B, Backmund M, Bruggmann P, Bruneau J, Bourgeois S et al.(2017). Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study. International Journal of Drug Policy vol. 47, 230-238.
10.1016/j.drugpo.2017.05.040
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25083
Grebely J, Dalgard O, Cunningham EB, Hajarizadeh B, Foster GR, Bruggmann P, Conway B, Backmund M et al.(2017). Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. International Journal of Drug Policy vol. 47, 177-186.
10.1016/j.drugpo.2017.05.020
Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C, Hickman M, Hellard M et al.(2017). Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy vol. 47, 51-60.
10.1016/j.drugpo.2017.05.019
Jones M, Cunningham ME, Wing P, DeSilva S, Challa R, Sheri A, Padmanabhan S, Iyer RP et al.(2017). SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. Journal of Medical Virology vol. 89, (9) 1620-1628.
10.1002/jmv.24809
Lamoury FMJ, Soker A, Martinez D, Hajarizadeh B, Cunningham EB, Cunningham P, Bruggmann P, Foster GR et al.(2017). Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. J Clin Virol vol. 92, 32-38.
10.1016/j.jcv.2017.05.007
De Silva S, Li W, Kemos P, Brindley J, Mecci J, Samsuddin S, Chin-Aleong J, Feakins R et al. (2017). NON-INVASIVE MARKERS OF LIVER FIBROSIS IN FATTY LIVER DISEASE ARE UNRELIABLE IN PEOPLE OF SOUTH ASIAN DESCENT. GUT. vol. 66, A164-A164.
10.1136/gutjnl-2017-314472.321
Heath H, Renney G, Ward M, Cutillas P, Kudu H, Goldin R, Hutchins R, Foster GR et al. (2017). STAT2 IS A KEY MEDIATOR OF ACUTE PANCREATITIS. GUT. vol. 66, A42-A42.
10.1136/gutjnl-2017-314472.80
Cunningham EB, Hajarizadeh B, Dalgard O, Amin J, Hellard M, Foster GR, Bruggmann P, Conway B et al.(2017). Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. BMC Infect Dis vol. 17, (1) 420-420.
10.1186/s12879-017-2517-3
https://qmro.qmul.ac.uk/xmlui/handle/123456789/34803
Robaeys G, Christensen S, Lucidarme D, Arain A, Bruggmann P, Kunkel J, Keim S, Jäkel M et al.(2017). Chronic Hepatitis C Treatment in Patients with Drug Injection History: Findings of the INTEGRATE Prospective, Observational Study. Infectious Diseases and Therapy vol. 6, (2) 265-275.
10.1007/s40121-017-0158-x
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25097
Williams R, Alexander G, Aspinall R, Bosanquet J, Camps-Walsh G, Cramp M, Day N, Dhawan A et al.(2017). New metrics for the Lancet Standing Commission on Liver Disease in the UK. Lancet vol. 389, (10083) 2053-2080.
10.1016/S0140-6736(16)32234-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/51163
Feld JJ, Foster GR(2017). Corrigendum to "Second generation direct-acting antivirals - do we expect major improvements?". J Hepatol vol. 66, (5)
10.1016/j.jhep.2017.02.015
Charlton M, Cheung MCM, Manns M, Sajed N, Troke PJF, Spellman J, Copans A, Arterburn S et al. (2017). Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and SOLAR-2 Studies Compared to a Real-world Dataset. TRANSPLANTATION. vol. 101, 92-92.
Vinaixa C, Foster G, Coilly A, Belli L, Mix H, Duvoux C, Berenguer M (2017). Safety and Efficacy of Interferon-free Antiviral Treatment in Patients with MELD over 20. TRANSPLANTATION. vol. 101, 92-93.
Feld JJ, Foster GR(2017). Second generation direct-acting antivirals - do we expect major improvements? (vol 66, pg s130, 2016). JOURNAL OF HEPATOLOGY vol. 66, (5) 1105-1105.
10.1016/j.jhep.2017.02.015
Ansari MA, Pedergnana V, L C Ip C, Magri A, Von Delft A, Bonsall D, Chaturvedi N, Bartha I et al.(2017). Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus. Nature Genetics vol. 49, (5) 666-673.
10.1038/ng.3835
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23087
Jacobson IM, Lawitz E, Gane EJ, Willems BE, Ruane PJ, Nahass RG, Borgia SM, Shafran SD et al.(2017). Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology vol. 153, (1) 113-122.
10.1053/j.gastro.2017.03.047
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25088
Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen VD, Habersetzer F, Manolakopoulos S, Negri E et al.(2017). Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Annals of Gastroenterology vol. 30, (3) 327-343.
10.20524/aog.2017.0136
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23615
Foster GR(2017). Chronic hepatitis C: less of a problem than first thought?. Lancet Gastroenterol Hepatol vol. 2, (3) 146-147.
10.1016/S2468-1253(16)30209-6
Vergis N, Khamri W, Beale K, Sadiq F, Aletrari MO, Moore C, Atkinson SR, Bernsmeier C et al.(2017). Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut vol. 66, (3) 519-529.
10.1136/gutjnl-2015-310378
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M et al.(2017). Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clinical Gastroenterology and Hepatology vol. 15, (3) 421-430.e6.
10.1016/j.cgh.2016.10.037
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23141
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F et al.(2017). Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One vol. 12, (1) e0168713-e0168713.
10.1371/journal.pone.0168713
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23465
De Silva S, Li W, Kemos P, Brindley JH, Feakins R, Chinaleong J, Samsuddin S, Foster GR et al. (2017). Blood-test based assessment of liver fibrosis, but not transient elastography, is less accurate in NAFLD patients of South Asian compared to White ethnicity. JOURNAL OF HEPATOLOGY. vol. 66, S595-S596.
10.1016/S0168-8278(17)31618-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25149
Holland-Fischer P, Shah N, Sawhney R, Privitera G, Spinella S, Masson S, Foster G, Aithal G et al. (2017). DASIMAR: a novel prognostic biomarker for acute cirrhosis decompensation to guide early intervention - a prospective multicenter study. JOURNAL OF HEPATOLOGY. vol. 66, S567-S567.
10.1016/S0168-8278(17)31553-2
Foster GR, Gane E, Asatryan A, Asselah T, Ruane PJ, Pol S, Poordad F, Stedman CA et al. (2017). ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naive HCV genotype 3-infected patients without cirrhosis. JOURNAL OF HEPATOLOGY. vol. 66, S33-S33.
10.1016/S0168-8278(17)30326-4
Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al. (2017). Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study. JOURNAL OF HEPATOLOGY. vol. 66, S503-S504.
10.1016/S0168-8278(17)31407-1
Puoti M, Foster G, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS et al. (2017). High SVR rates with eight and twelve weeks of pangenotypic glecaprevir/pibrentasvir: integrated efficacy and safety analysis of genotype 1-6 patients without cirrhosis. JOURNAL OF HEPATOLOGY. vol. 66, S721-S721.
10.1016/S0168-8278(17)31927-X
Le Bert N, Rivino L, Gill US, Cheng Y, Kunasegaran K, Tan DZ, Becht E, Hansi NK et al. (2017). PD-1+CD8+T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B. JOURNAL OF HEPATOLOGY. vol. 66, S687-S687.
10.1016/S0168-8278(17)31847-0
Cheung MC, Filipe A, Walker A, Mutimer DJ, Agarwal K, Aldersley M, MacDonald D, Khakoo S et al. (2017). Re-treatment of patients with decompensated chronic hepatitis C virus cirrhosis using 24 weeks of sofosbuvir and NS5A inhibitor, with or without ribavirin after failing a 12 week course. JOURNAL OF HEPATOLOGY. vol. 66, S84-S85.
10.1016/S0168-8278(17)30434-8
Irving WL, McLauchlan J, Foster G, UK HCVR (2017). Real world outcomes of DAA therapy for chronic hepatitis C virus infection in the HCV Research UK National cohort. JOURNAL OF HEPATOLOGY. vol. 66, S504-S504.
10.1016/S0168-8278(17)31408-3
Grebley J, Puoti M, Wedemeyer H, Cooper C, Sulkowski MS, Foster G, Berg T, Villa E et al. (2017). Safety and efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir with or without ribavirin in chronic hepatitis C patients receiving opioid substitution therapy: a pooled analysis across 12 clinical trials. JOURNAL OF HEPATOLOGY. vol. 66, S514-S514.
10.1016/S0168-8278(17)31430-7
Sulkowski M, Foster G, Shiffman M, Byrne S, Wolf J, Grabowski C, McNally J, Brainard D et al. (2017). Safety and efficacy of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C in patients aged 65 years or older: a retrospective analysis of phase 3 studies. JOURNAL OF HEPATOLOGY. vol. 66, S719-S719.
Foster G, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD et al. (2017). Successful treatment of patients with HCV GT3 infection and cirrhosis with elbasvir/grazoprevir plus sofosbuvir does not correct insulin resistance by 12 weeks post-treatment. JOURNAL OF HEPATOLOGY. vol. 66, S504-S505.
10.1016/S0168-8278(17)31409-5
Hezode C, Fried MW, Colombo M, Bourliere M, Spengler U, Ben-Ari Z, Strasser SI, Perumalswami P et al. (2016). Efficacy and Safety of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Virus Infection and Inherited Blood Disorders: Final Data from the C-Edge Ibld Study. BLOOD. vol. 128,
10.1182/blood.V128.22.1303.1303
Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A et al.(2016). Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Clin Infect Dis vol. 63, (11) 1479-1481.
10.1093/cid/ciw579
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16011
Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D et al.(2016). IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Springerplus vol. 5, (1) 1990-1990.
10.1186/s40064-016-3663-6
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18367
Lewis H, Kunkel J, Axten D, Dalton J, Gardner H, Tippett A, Wynne S, Wilkinson M et al.(2016). Community nurse-led initiation of antiviral therapy for chronic hepatitis C in people who inject drugs does not increase uptake of or adherence to treatment. Eur J Gastroenterol Hepatol vol. 28, (11) 1258-1263.
10.1097/MEG.0000000000000711
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16010
Marcellin P, Ahn SH, Chuang W-L, Hui AJ, Tabak F, Mehta R, Petersen J, Lee C-M et al.(2016). Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B. Aliment Pharmacol Ther vol. 44, (9) 957-966.
10.1111/apt.13779
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25145
Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N et al.(2016). Ribavirin-Free Regimen with Sofosbuvir and Velpatasvir Is Associated with High Efficacy and Improvement of Patient-Reported Outcomes in Patients with Genotypes 2 and 3 Chronic Hepatitis C: Results from Astral-2 and -3 Clinical Trials. Clinical Infectious Diseases vol. 63, (8) 1042-1048.
10.1093/cid/ciw496
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16002
Foster GR, Agarwal K, Cramp M, Moreea S, Barclay ST, Collier J, Brown AS, Ryder SD et al. (2016). C-ISLE: Grazoprevir/Elbasvir plus Sofosbuvir in Treatment-naive and Treatment-experienced HCV GT3 Cirrhotic Patients Treated for 8, 12 or 16 weeks. HEPATOLOGY. vol. 64, 39A-40A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/19346
Verma S, Foster GR, Sadler MD, Heneghan MA, Irving W, Considine AB, Childs K, Suddle A et al. (2016). Decreased health resource utilization by peri-transplant (PT) HCV patients after successful direct acting antiviral (DAA) therapy. HEPATOLOGY. vol. 64, 459A-460A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20620
Welzel TM, Kwo PY, Jacobson IM, Zhang J, De-Oertel S, McNally J, Brainard DM, McHutchison JG et al. (2016). Factors Associated with Persistent Alanine Aminotransferase Elevation in Patients Treated with Ledipasvir/Sofosbuvir or Sofosbuvir/Velpatasvir. HEPATOLOGY. vol. 64, 449A-449A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20639
Tran TT, Feld JJ, Foster GR, Naik S, Eggleton ES, Zhang J, Natha M, Llewellyn J et al. (2016). Gender Differences in Patients Treated for HCV: Efficacy and Safety of Sofosbuvir/Velpatasvir in Women. HEPATOLOGY. vol. 64, 422A-422A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23494
Marcellin P, Seto W-K, Hu C-T, Yurdaydin C, Foster GR, Flaherty JF, Kim K, Suri V et al. (2016). Genotype Specific Differences In Magnitude Of HBsAg Reduction During TDF or tenofovir alfenamide (TAF) Therapy In CHB Patients. HEPATOLOGY. vol. 64, 918A-918A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18442
Charlton MR, Cheung MC, Manns MP, Sajed N, Troke P, Spellman JG, Copans A, Arterburn S et al. (2016). Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset. HEPATOLOGY. vol. 64, 489A-490A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23495
Iser D, Lawitz EJ, Ruane P, Stedman C, Foster G, Mir HM, Hyland RH, Coogan S et al.(2016). Long-term follow-up of patients with chronic HCV infection following treatment with direct acting antiviral regimens: maintenance of SVR, persistence of resistance mutations, and clinical outcomes. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 31, 74-75.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25991
Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ, Brown A, Gelson WTH et al.(2016). Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology vol. 65, (4) 741-747.
10.1016/j.jhep.2016.06.019
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15986
Shafran S, Shaw D, Charafeddine M, Agarwal K, Foster GR, Abunimeh M, Fu B, Pilot-Matias T et al. (2016). QUARTZ II-III: Final Efficacy and Safety Results in Patients with HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/Ritonavir and Sofosbuvir With or Without Ribavirin. HEPATOLOGY. vol. 64, 440A-440A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/23142
Feld JJ, Foster GR(2016). Second generation direct-acting antivirals - Do we expect major improvements?. J Hepatol vol. 65, (1 Suppl) S130-S142.
10.1016/j.jhep.2016.07.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/37863
Agarwal K, Schultz M, Pianko S, Bank L, Collier J, George J, Priest M, Ryder SD et al. (2016). Sofosbuvir plus Peginterferon plus Ribavirin for 12 Weeks in Genotype 3 HCV Infected Patients and Treatment-Experienced Cirrhotic Patients with Genotype 2 HCV Who Did Not Achieve SVR after 16 or 24 Weeks of Sofosbuvir plus Ribavirin. HEPATOLOGY. vol. 64, 455A-456A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20679
Foster GR, Zeuzem S, Gane EJ, Stedmar CA, Feld JJ, Mangia A, Agarwal K, Swain MG et al. (2016). Sofosbuvir-Based All-Oral Regimens for Patients with Chronic Hepatitis C Genotype 3 Infection: Integrated Analysis of Five Clinical Studies. HEPATOLOGY. vol. 64, 955A-956A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20659
Younossi ZM, Stepanova M, Feld JJ, Zeuzem S, Sulkowski MS, Foster GR, Mangia A, Charlton MR et al. (2016). Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics. HEPATOLOGY. vol. 64, 12A-12A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/20699
Foster GR, Chayama K, Chuang W-L, Fainboim H, Farkkila M, Gadano A, Gaeta GB, Hézode C et al.(2016). A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3. Springerplus vol. 5, (1) 1365-1365.
10.1186/s40064-016-2920-z
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15696
Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PTF(2016). Interferon Alpha Induces Sustained Changes in NK Cell Responsiveness to Hepatitis B Viral Load Suppression In Vivo. PLOS Pathogens vol. 12, (8) e1005788-e1005788.
10.1371/journal.ppat.1005788
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15242
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Ryan R et al.(2016). An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1). PLoS One vol. 11, (7) e0158526-e0158526.
10.1371/journal.pone.0158526
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15774
Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ et al.(2016). Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation. Journal of Hepatology vol. 65, (1) 17-25.
10.1016/j.jhep.2016.02.007
Foster GR, Irving WL, Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ et al.(2016). Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology vol. 64, (6) 1224-1231.
10.1016/j.jhep.2016.01.029
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12876
Hewett N, Buchman P, Musariri J, Sargeant C, Johnson P, Abeysekera K, Grant L, Oliver EA et al.(2016). Randomised controlled trial of GP-led in-hospital management of homeless people ('Pathway). Clinical Medicine vol. 16, (3) 223-229.
10.7861/clinmedicine.16-3-223
https://qmro.qmul.ac.uk/xmlui/handle/123456789/13703
Orkin C, Jeffery-Smith A, Foster GR, Tong CYW(2016). Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?. BMJ Open vol. 6, (5) e010661-e010661.
10.1136/bmjopen-2015-010661
https://qmro.qmul.ac.uk/xmlui/handle/123456789/16003
Li H, Chen L-Y, Zhang N-N, Li S-T, Zeng B, Pavesi M, Amorós À, Mookerjee RP et al.(2016). Characteristics, Diagnosis and Prognosis of Acute-on-Chronic Liver Failure in Cirrhosis Associated to Hepatitis B. Scientific Reports vol. 6, 25487-25487.
10.1038/srep25487
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15327
Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM et al.(2016). Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Ann Hepatol vol. 15, (3) 333-349.
10.5604/16652681.1198803
Foster GR(2016). Reply to: “High mortality during direct acting antiviral therapy for hepatitis C patients with Child’s C cirrhosis: Results of the Irish Early Access Programme”. Journal of Hepatology
10.1016/j.jhep.2016.04.011
Foster GR, Mangia A, Sulkowski M(2016). Sofosbuvir and Velpatasvir for Patients with HCV Infection. N Engl J Med vol. 374, (17) 1687-1688.
10.1056/NEJMc1601160
Jensen D, Asselah T, Dieterich D, Foster G, Sulkowski M, Zeuzem S, Mantry P, Yoshida E et al.(2016). Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. Annals of Hepatology vol. 15, (3) 333-349.
10.5604/16652681.1198803
Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML et al.(2016). Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. PLoS One vol. 11, (3) e0151703-e0151703.
10.1371/journal.pone.0151703
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17605
Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al.(2016). Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: The "Going Viral" campaign. HIV Medicine vol. 17, (3) 222-230.
10.1111/hiv.12364
Foster GR, Ferenci P, Asselah T, Mantry P, Dufour J-F, Bourlière M, Forton D, Maevskaya M et al.(2016). Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin. J Viral Hepat vol. 23, (3) 227-231.
10.1111/jvh.12485
Cheung M, Foster G, Irving W, McLauchlan J, Walker A, Hudson B, Verma S, Agarwal K (2016). Antiviral treatment in patients with advanced hepatitis C virus cirrhosis with sofosbuvir and either ledipasvir or daclatasvir, with or without ribavirin: observational cohort study. LANCET. vol. 387, 26-26.
Rivino L, Le Bert N, Gill U, Cheng Y, Kunasegaran K, Tan D, Koh S, Hansi N et al. (2016). AN IMMUNOLOGICAL BIOMARKER TO PREDICT HEPATIC FLARES UPON NUC THERAPY DISCONTINUATION IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 64, S164-S165.
10.1016/S0168-8278(16)01672-X
Cheung MCM, Foster GR, Irving WL, Walker AJ, Hudson BE, Verma S, McLauchlan J, Mutimer DJ et al. (2016). ANTIVIRAL TREATMENT IN PATIENTS WITH ADVANCED HCV CIRRHOSIS USING SOFOSBUVIR AND LEDIPASVIR/DACLATASVIR WITH OR WITHOUT RIBAVIRIN-6 AND 12 MONTH OUTCOMES COMPARED TO UNTREATED PATIENTS. JOURNAL OF HEPATOLOGY. vol. 64, S185-S186.
10.1016/S0168-8278(16)01699-8
Martin NK, Vickerman P, Dore GJ, Grebely J, Miners A, Cairns J, Foster GR, Hutchinson SJ et al. (2016). COMPARING INDIVIDUAL AND POPULATION PREVENTION BENEFITS OF EARLY DIRECT-ACTING ANTIVIRAL TREATMENT FOR HCV. JOURNAL OF HEPATOLOGY. vol. 64, S464-S464.
10.1016/S0168-8278(16)00779-0
Marcellin P, Ahn SH, Ma X, Caruntu FA, Tak WY, Elkashab M, Chuang W-L, Lim S-G et al.(2016). Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. Gastroenterology vol. 150, (1) 134-144.e10.
10.1053/j.gastro.2015.09.043
Marcellin P, Xie Q, Paik SW, Flisiak R, Piratvisuth T, Petersen J, Asselah T, Cornberg M et al. (2016). EFFECTIVENESS OF PEGINTERFERON ALFA-2A THERAPY IN HBEAG-POSITIVE AND HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B: FINAL RESULTS 3 YEARS POST-TREATMENT OF THE PROSPECTIVE, GLOBAL, OBSERVATIONAL S-COLLATE STUDY. JOURNAL OF HEPATOLOGY. vol. 64, S598-S599.
10.1016/S0168-8278(16)01105-3
Foster G, Gane E, Asatryan A, Pol S, Poordad F, Vierling J, Kort J, Lin C-W et al. (2016). ENDURANCE-3: A PHASE 3, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY TO COMPARE EFFICACY AND SAFETY OF ABT-493/ABT-530 TO SOFOSBUVIR CO-ADMINISTERED WITH DACLATASVIR IN ADULTS WITH HCV GENOTYPE 3 INFECTION. JOURNAL OF HEPATOLOGY. vol. 64, S292-S292.
10.1016/S0168-8278(16)00366-4
Wei L, Pavlovic V, Bansal AT, Chen X-P, Foster GR, He H, Kao J-H, Lampertico P et al. (2016). GENETIC VARIATION IN FCER1A GENE PREDICTS SUSTAINED HBSAG CLEARANCE IN EAST-ASIAN PATIENTS TREATED WITH PEGYLATED INTERFERON ALFA-2A (40KD): THE "PEG-BE-YOND" STUDY. JOURNAL OF HEPATOLOGY. vol. 64, S603-S603.
10.1016/S0168-8278(16)01114-4
Ansari MA, Pedergnana V, Bonsall D, Chaturvedi N, Bartha I, Fellay J, Smith D, Bowden R et al. (2016). GENOME-TO-GENOME VIRUS-HOST ANALYSIS REVEALS HCV GENOTYPE 3 VIRAL POLYMORPHISMS LINKED VIRAL LOADAND TO HOST HLA CLASS-I/II AND IL28B ALLELES. JOURNAL OF HEPATOLOGY. vol. 64, S419-S419.
Lamoury F, Soker A, Martinez D, Hajarizadeh B, Cunningham E, Bruggmann P, Foster G, Dalgard O et al. (2016). HEPATITIS C VIRUS CORE ANTIGEN: A SIMPLIFIED TREATMENT MONITORING TOOL, INCLUDING FOR POST-TREATMENT RELAPSE. JOURNAL OF HEPATOLOGY. vol. 64, S625-S626.
10.1016/S0168-8278(16)01163-6
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ari ZB, Foster GR et al. (2016). HIGH EFFICACY OF AN 8-WEEK 3-DRUG REGIMEN OF GRAZOPREVIR/MK-8408/MK-3682 IN HCV GENOTYPE 1, 2 AND 3-INFECTED PATIENTS: SVR24 DATA FROM THE PHASE 2 C-CREST 1 AND 2 STUDIES. JOURNAL OF HEPATOLOGY. vol. 64, S759-S759.
10.1016/S0168-8278(16)01479-3
Sinkala E, Kapulu MC, Besa E, Zyambo K, Chisoso NJ, Foster GR, Kelly P(2016). Hepatosplenic schistosomiasis is characterised by high blood markers of translocation, inflammation and fibrosis. Liver Int vol. 36, (1) 145-150.
10.1111/liv.12891
Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M et al. (2016). IMPRESSIVE GAINS IN PATIENT-REPORTED OUTCOMES ARE OBSERVED IN CHRONIC HEPATITIS C PATIENTS WITH OR WITHOUT CIRRHOSIS WHO ARE TREATED WITH SOFOSBUVIR AND VELPATASVIR: RESULTS FROM ASTRAL-1,-2,-3 AND-4. JOURNAL OF HEPATOLOGY. vol. 64, S629-S629.
Lawitz EJ, Ruane P, Stedman C, Foster G, Hyland RH, Coogan S, Moody S, Dvory-Sobol H et al. (2016). LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HCV INFECTION FOLLOWING TREATMENT WITH DIRECT ACTING ANTIVIRAL REGIMENS: MAINTENANCE OF SVR, PERSISTENCE OF RESISTANCE MUTATIONS AND CLINICAL OUTCOMES. JOURNAL OF HEPATOLOGY. vol. 64, S612-S613.
10.1016/S0168-8278(16)01134-X
Dyson JK, Hutchinson J, Harrison L, Rotimi O, Tiniakos D, Foster GR, Aldersley MA, McPherson S(2016). Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use. J Hepatol vol. 64, (1) 234-238.
10.1016/j.jhep.2015.07.041
Wing P, Filipe A, Cunningham ME, De Silva S, Cheung M, Jones M, Irving W, McLauchlan J et al. (2016). PRE-TREATMENT REDUCTION IN SENSITIVITY TO SOFOSBUVIR AND RIBAVIRIN IN PATIENTS WITH GENOTYPE 3 HEPATITIS C VIRUS WHO RELAPSE FOLLOWING ALL ORAL ANTIVIRAL THERAPY. JOURNAL OF HEPATOLOGY. vol. 64, S407-S408.
10.1016/S0168-8278(16)00648-6
Jacobson I, Brau N, Bourgeois S, Mathurin P, Thuluvath P, Fessel WJ, Ryder S, Gerken G et al. (2016). THE TOLERABILITY OF SOF/VEL FOR 12 WEEKS IN > 1,000 PATIENTS TREATED IN THE ASTRAL-1, ASTRAL-2, AND ASTRAL-3 STUDIES: AN INTEGRATED SAFETY ANALYSIS. JOURNAL OF HEPATOLOGY. vol. 64, S773-S774.
10.1016/S0168-8278(16)01508-7
Foster GR, Afdhal N, Roberts SK, Br N, Gane EJ, Pianko S, Lawitz E, Thompson A et al.(2015). Sofosbuvir and velpatasvir for HCV Genotype 2 and 3 infection. New England Journal of Medicine vol. 373, (27) 2608-2617.
10.1056/NEJMoa1512612
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17933
Shafran S, Shaw D, Cohen E, Agarwal K, Foster GR, Abunimeh M, Cohen DE, Gane EJ(2015). High Rates of SVR in Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/r and Sofosbuvir with or without Ribavirin. HEPATOLOGY vol. 62, (6) 1390A-1390A.
Gane EJ, Pianko S, Roberts SK, Thompson AJ, Zeuzem S, Zuckerman E, Ben Ari Z, Foster GR et al.(2015). Phase 2, Randomized, Open-Label Clinical Trials of the Efficacy and Safety of Grazoprevir and MK-3682 (NS5B Polymerase Inhibitor) with Either Elbasvir or MK-8408 (NS5A Inhibitor) in Patients with Chronic HCV GT1, 2 or 3 Infection (Part A of C-CREST-1 & 2). HEPATOLOGY vol. 62, (6) 1389A-1389A.
Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, Day N, Dhawan A et al.(2015). Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet vol. 386, (10008) 2098-2111.
10.1016/S0140-6736(15)00680-7
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11094
Chan HL-Y, Elkhashab M, Trinh H, Tak WY, Ma X, Chuang W-L, Kim YJ, Martins EB et al.(2015). Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J Hepatol vol. 63, (5) 1086-1092.
10.1016/j.jhep.2015.06.025
Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, Barnes E, Brainard DM et al.(2015). Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon-Alfa in Patients with Hepatitis C Virus Genotype 3 Infection and Treatment-Experienced Patients with Cirrhosis and Hepatitis C Virus Genotype 2 Infection. Gastroenterology vol. 149, (6) 1462-1470.
10.1053/j.gastro.2015.07.043
Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR et al.(2015). Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection. Hepatology vol. 62, (4) 1013-1023.
10.1002/hep.27960
Gill US, Rivino L, Le Bert N, Kunasegaran K, Tan D, Koh S, Van den Berg M, Cheng Y et al. (2015). Characterisation of the immune profile in Chronic Hepatitis B, with CyTOF, to identify biomarkers of immune control following NUC therapy discontinuation. HEPATOLOGY. vol. 62, 294A-294A.
Chan HL-Y, Ahn SH, Chuang W-L, Tabak F, Mehta R, Petersen J, Wu G, Martins EB et al. (2015). Early Decline in Serum HBsAg at Week 4 and 12 of Therapy with Tenofovir Disoproxil Fumarate and Pegylated Interferon is Predictive of HBsAg Loss. HEPATOLOGY. vol. 62, 1190A-1190A.
Verma S, Foster GR, Irving W, McLauchlan J, Cheung MC, Hudson BE, Carey I, Agarwal K (2015). Health resource usage in peri-transplant patients during 12 weeks of therapy with sofosbuvir (SOF), with or without ribavirin (RBV) and an NS5A inhibitor. HEPATOLOGY. vol. 62, 789A-790A.
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxi A, Buggisch P, Sanai FM et al. (2015). High efficacy of a 12-week simeprevir plus peginterferon alfa 2a/ribavirin regimen in treatment-naive patients with chronic HCV genotype 4 infection and mild-to-moderate fibrosis. HEPATOLOGY. vol. 62, 792A-793A.
Gill US, Peppa D, Micco L, Singh HD, Carey I, Foster GR, Maini MK, Kennedy PT (2015). NK cell function is restored with sequential NUC therapy and correlates with treatment response in Chronic Hepatitis B. HEPATOLOGY. vol. 62, 1001A-1002A.
Hansi NK, Seipt CC, Gill US, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). Quantitative Hepatitis B surface antigen (qHBsAg) may define low-risk inactive carriers of CHB: Can this provide a framework for better management across all age-groups?. HEPATOLOGY. vol. 62, 976A-977A.
Verma S, Carey I, Childs KE, Ayers A, Morgan P, Considine AB, Oakes K, Heneghan MA et al. (2015). Ribavirin levels at treatment weeks (TW) 4-6 can predict sustained viriological response (SVR12) in HCV cirrhotic patients treated with all oral direct-acting antiviral therapy (DAAs). HEPATOLOGY. vol. 62, 750A-750A.
Mangia A, Roberts SK, Pianko S, Thompson AJ, Cooper C, Conway B, Bourliere M, Asselah T et al. (2015). Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study. HEPATOLOGY. vol. 62, 338A-339A.
Chan HL-Y, Ahn SH, Chuang W-L, Tabak F, Mehta R, Petersen J, Kim K, Dinh P et al. (2015). Treatment and HBeAg-status Differentiate Clinical Outcomes Following ALT Flares - Analysis of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon (PEG) Combination Study for Chronic Hepatitis B (CHB). HEPATOLOGY. vol. 62, 333A-334A.
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster G, Craxi A, Buggisch P, Sanai F et al.(2015). Efficacy and safety of a 12-week simeprevir plus peginterferon/ribavirin regimen in treatment-naive HCV genotype 4-infected patients with mild-to-moderate fibrosis. JOURNAL OF VIRAL HEPATITIS vol. 22, 25-25.
Strasser S, Chan H, Ahn S, Chuang W, Hui A, Tabak F, Mehta R, Petersen J et al.(2015). Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB). JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 30, 91-92.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11303
Pianko S, Cooper C, Brown A, Forton D, Nahass R, George J, Barnes E, Brainard D et al.(2015). Sofosbuvir plus Peginterferon/Ribavirin for 12 weeks vs. Sofosbuvir plus Ribavirin for 16 or 24 weeks in genotype 3 HCV infected patients and treatment-experienced cirrhotic patients with genotype 2 HCV: the BOSON study. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 30, 90-90.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/11123
Zeuzem S, Gane E, Agarwal K, Cohen D, Xie W, Dylla D, Tatsch F, Foster G(2015). Sustained virologic response rates in HCV genotype 1-infected patients treated for 8 weeks with ombitasvir/paritaprevir/r and dasabuvir with ribavirin. JOURNAL OF VIRAL HEPATITIS vol. 22, 27-27.
Foster G(2015). Which DAA regime should include ribavirin?. JOURNAL OF VIRAL HEPATITIS vol. 22, 2-3.
Rivino L, Van Den Berg M, Gill US, Le Bert N, Koh S, Hansi NK, Newell E, Foster GR et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILE IN CHRONIC HEPATITIS B PATIENTS FOLLOWING NUCLEOS (T)IDE DISCONTINUATION BY CYTOF MASS CYTOMETRY. GUT. vol. 64, A106-A107.
10.1136/gutjnl-2015-309861.218
Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). DEFINING THE LOW-RISK INACTIVE CARRIER IN CHRONIC HEPATITIS B WITH QHBSAG: DO THE SAME RULES APPLY IN CHILDREN AND YOUNG ADULTS?. GUT. vol. 64, A108-A109.
10.1136/gutjnl-2015-309861.222
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBSAG DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHB. GUT. vol. 64, A113-A113.
10.1136/gutjnl-2015-309861.231
Hansi N, Gill US, Banerjee M, Naik S, Tong W, Foster GR, Carey I, Kennedy PT (2015). IDENTIFYING TRUE IMMUNE-TOLERANT DISEASE IN CHILDREN AND YOUNG ADULTS WITH CHB USING QUANTIFIED HEPATITIS B SURFACE ANTIGEN LEVELS. GUT. vol. 64, A108-A108.
10.1136/gutjnl-2015-309861.221
Tai D, Lewis H, Derwa Y, Lillis A, Reynolds T, Maitland K, Hall D, Alazawi W et al. (2015). ONE YEAR MORTALITY OUTCOMES OF PATIENTS WITH LIVER CIRRHOSIS ADMITTED TO A TEACHING HOSPITAL INTENSIVE CARE UNIT. GUT. vol. 64, A448-A449.
10.1136/gutjnl-2015-309861.981
Foster GR, Asselah T, Moreno C, Sarrazin C, Gschwantler M, Craxi A, Buggisch P, Ryan R et al. (2015). SAFETY AND EFFICACY OF SIMEPREVIR (SMV) PLUS PEG-IFN/RBV IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS ELIGIBLE FOR 12 WEEKS OF TREATMENT. GUT. vol. 64, A468-A469.
10.1136/gutjnl-2015-309861.1025
Gill US, Hansi NK, Payaniandy L, Schulz J, Payaniandy D, Alazawi W, Dearden J, Kallis YN et al. (2015). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON PROVIDES A GREATER DECLINE IN HBSAG AND POTENTIALLY OFFERS A TREATMENT ADVANTAGE OVER CURRENT THERAPIES. GUT. vol. 64, A113-A113.
10.1136/gutjnl-2015-309861.232
Ferenci P, Asselah T, Foster GR, Zeuzem S, Sarrazin C, Moreno C, Ouzan D, Maevskaya M et al.(2015). STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Journal of Hepatology vol. 62, (6) 1246-1255.
10.1016/j.jhep.2014.12.024
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7119
Alazawi W, Heath H, Petts G, Kudu H, Feakins R, O'Brien A, Goldin R, Foster GR (2015). STAT2 IS A KEY INFLAMMATORY MOLECULE IN HUMAN NON-ALCOHOLIC FATTY LIVER DISEASE AND MURINE LIVER INJURY. GUT. vol. 64, A452-A453.
10.1136/gutjnl-2015-309861.990
Hassanein T, Roberts S, Shafran SD, Makara M, Bennett M, Muellhaupt B, Poordad F, Ryder S et al. (2015). ADHERENCE TO OMBITASVIR/PARITAPREVIR/R, DASABUVIR, AND RIBAVIRIN IS > 98% IN THE SAPPHIRE-I AND SAPPHIRE-II TRIALS. JOURNAL OF HEPATOLOGY. vol. 62, S685-S685.
10.1016/S0168-8278(15)31111-9
Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxi A, Buggisch P, Ryan R et al. (2015). BASELINE FACTORS ASSOCIATED WITH INCREASED SVR RATES IN 123 TREATMENT-NAIVE CHRONIC HCV GENOTYPE 1 PATIENTS TREATED WITH A SHORTENED 12-WEEK SIMEPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN REGIMEN: A MULTIVARIATE ANALYSIS. JOURNAL OF HEPATOLOGY. vol. 62, S629-S630.
10.1016/S0168-8278(15)30995-8
Brown A, Hezode C, Zuckerman E, Foster G, Zekry A, Roberts S, Howe A, Durkan C et al. (2015). C-SCAPE: EFFICACY AND SAFETY OF 12 WEEKS OF GRAZOPREVIR plus /- ELBASVIR plus /- RIBAVIRIN IN PATIENTS WITH HCV GT2, 4, 5 OR 6 INFECTION. JOURNAL OF HEPATOLOGY. vol. 62, S619-S619.
10.1016/S0168-8278(15)30974-0
Rivino L, Van Den Berg M, Le Bert N, Koh S, Gill US, Hansi NK, Foster GR, Bertoletti A et al. (2015). CHARACTERISATION OF THE IMMUNE PROFILES OF CHRONIC HEPATITIS B PATIENTS FOLLOWING NUC DISCONTINUATION BY CyTOF MASS CYTOMETRY. JOURNAL OF HEPATOLOGY. vol. 62, S491-S491.
10.1016/S0168-8278(15)30682-6
Vermehren J, Perner D, Clark D, Susser S, Hubb J, Zeuzem S, Foster G, Sarrazin C (2015). CLINICAL UTILITY OF THE ARTUS HCV QS-RGQ ASSAY FOR HCVRNA QUANTIFICATION. JOURNAL OF HEPATOLOGY. vol. 62, S597-S597.
10.1016/S0168-8278(15)30930-2
Cunningham ME, Javaid A, Waters J, Davidson-Wright J, Wong JLC, Jones M, Foster GR(2015). Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C. Hepatology vol. 61, (4) 1192-1204.
10.1002/hep.27570
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7114
Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance H, O'Dwyer M, Owen H, O'Brien A et al. (2015). EARLY MONOCYTE DYSFUNCTION IN PATIENTS WHO DEVELOP SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS) AND SEPSIS AFTER HEPATOPANCREATICOBILIARY SURGERY. JOURNAL OF HEPATOLOGY. vol. 62, S290-S291.
10.1016/S0168-8278(15)30209-9
Grebely J, Dalgard O, Conway B, Foster G, Bruggmann P, Backmund M, Robaeys G, Swan T et al. (2015). EFFICACY OF RESPONSE-GUIDED PEGYLATED INTERFERON AND RIBAVIRIN THERAPY FOR PEOPLE WHO INJECT DRUGS WITH HCV GENOTYPE 2/3 INFECTION: THE ACTIVATE STUDY. JOURNAL OF HEPATOLOGY. vol. 62, S657-S657.
10.1016/S0168-8278(15)31050-3
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PT (2015). FUNCTIONAL IMMUNE RESTORATION CORRELATES WITH HBsAg DECLINE AND MAY PREDICT TREATMENT RESPONSE ON SEQUENTIAL NUC THERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 62, S496-S496.
10.1016/S0168-8278(15)30693-0
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N et al.(2015). HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact. J Viral Hepat vol. 22, (4) 399-408.
10.1111/jvh.12338
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7600
Wedemeyer H, Berg T, Flamm SL, Foster GR, Craxi A, Larrey D, Morgan TR, Fried MW et al. (2015). IMPROVEMENT IN LIVER FUNCTION AND NON-INVASIVE ESTIMATES OF LIVER FIBROSIS 48 WEEKS AFTER TREATMENT WITH OMBITASVIR/PARITAPREVIR/R, DASABUVIR AND RIBAVIRIN IN HCV GENOTYPE 1 PATIENTS WITH CIRRHOSIS. JOURNAL OF HEPATOLOGY. vol. 62, S637-S638.
10.1016/S0168-8278(15)31011-4
Mathew S, Petrova M, Hendy J, de Lusignan S, Zamani J, Tiwari R, Nicholls M, Kennedy P et al. (2015). PERCEPTIONS OF VIRAL HEPATITIS TESTING IN MIGRANT COMMUNITIES AND THE PRIMARY CARE PHYSICIANS THAT SERVE THEM. JOURNAL OF HEPATOLOGY. vol. 62, S830-S830.
10.1016/S0168-8278(15)31455-0
Chan HL, Ahn SH, Chuang WL, Hui AJ, Tabak F, Mehta R, Petersen J, Lee C-M et al. (2015). PREDICTORS OF CLINICAL RESPONSE: RESULTS FROM A LARGE, RANDOMIZED CONTROLLED STUDY WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) PLUS PEGINTERFERON ALFA-2A (PEG) COMBINATION FOR CHRONIC HEPATITIS B (CHB). JOURNAL OF HEPATOLOGY. vol. 62, S251-S252.
10.1016/S0168-8278(15)30136-7
Kunkel J, Sweeney L, Falla A, Veldhuijzen I, Foster GR (2015). SCREENING FOR VIRAL HEPATITIS AMONG MIGRANTS IN THE EU: WHAT LESSONS CAN WE LEARN FROM POOR RESPONSE TO A PILOT TRIAL USING GP REGISTERS?. JOURNAL OF HEPATOLOGY. vol. 62, S838-S838.
10.1016/S0168-8278(15)31472-0
Foster GR, Pianko S, Cooper C, Brown A, Forton D, Nahass RG, George J, Barnes E et al. (2015). SOFOSBUVIR plus PEGINTERFERON/RIBAVIRIN FOR 12 WEEKS VS SOFOSBUVIR plus RIBAVIRIN FOR 16 OR 24 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH GENOTYPE 2 HCV: THE BOSON STUDY. JOURNAL OF HEPATOLOGY. vol. 62, S259-S260.
10.1016/S0168-8278(15)30151-3
Asselah T, Charlton M, Feld J, Foster GR, Mcnally J, Brainard DM, McHutchison JG, Mangia A et al. (2015). THE ASTRAL STUDIES: EVALUATION OF SOF/GS-5816 SINGLE TABLET REGIMEN FOR THE TREATMENT OF GENOTYPE 1-6 HCV INFECTION. JOURNAL OF HEPATOLOGY. vol. 62, S855-S856.
10.1016/S0168-8278(15)31511-7
Foster GR, McLauchlan J, Irving W, Cheung M, Hudson B, Verma S, Agarwal K, Grp HCVRUKEAP (2015). TREATMENT OF DECOMPENSATED HCV CIRRHOSIS IN PATIENTS WITH DIVERSE GENOTYPES: 12 WEEKS SOFOSBUVIR AND NS5A INHIBITORS WITH/WITHOUT RIBAVIRIN IS EFFECTIVE IN HCV GENOTYPES 1 AND 3. JOURNAL OF HEPATOLOGY. vol. 62, S190-S191.
10.1016/S0168-8278(15)30009-X
Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY (2015). UNEXPECTED HIGH PREVALENCE OF HCV-VIRAEMIA (HCV RNA plus ) IN THE EMERGENCY DEPARTMENT (ED) OF A LONDON HOSPITAL - SHOULD WE BE SCREENING FOR HCV IN ED ATTENDEES?. JOURNAL OF HEPATOLOGY. vol. 62, S825-S825.
10.1016/S0168-8278(15)31544-0
Foster GR(2015). Shorter treatments for hepatitis C: another step forward?. Lancet vol. 385, (9973) 1054-1055.
10.1016/S0140-6736(14)61600-7
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6965
Sweeney L, Owiti JA, Beharry A, Bhui K, Gomes J, Foster GR, Greenhalgh T(2015). Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals. BMC Health Serv Res vol. 15,
10.1186/s12913-015-0746-y
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7440
Petersen J(2015). Do we need more nucleos(t)ide analogs for the treatment of chronic hepatitis B?. Journal of Hepatology vol. 62, (3) 505-507.
10.1016/j.jhep.2014.12.003
Head MG, Fitchett JR, Cooke GS, Foster GR, Atun R(2015). Systematic analysis of funding awarded for viral hepatitis-related research to institutions in the United Kingdom, 1997-2010. J Viral Hepat vol. 22, (3) 230-237.
10.1111/jvh.12300
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7626
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E et al.(2015). Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. Journal of Hepatology vol. 62, (3) 533-540.
10.1016/j.jhep.2014.10.035
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7019
Foster GR, Gore C, Hudson M, Moss P, Ustianowski A, Ryder S, Bhagani S(2015). Response from Hepatitis C Trust, BASL, BIA, BVHG, BSG, and BHIVA to article asking whether widespread screening for hepatitis C is justified. BMJ vol. 350,
10.1136/bmj.h998
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7743
Owiti JA, Greenhalgh T, Sweeney L, Foster GR, Bhui KS(2015). Illness perceptions and explanatory models of viral hepatitis B & C among immigrants and refugees: a narrative systematic review. BMC public health vol. 15,
10.1186/s12889-015-1476-0
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6987
ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW(2015). High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?. Epidemiology and Infection
10.1017/S0950268815000199
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7778
Gill US, Zissimopoulos A, Al-Shamma S, Burke K, McPhail MJW, Barr DA, Kallis YN, Marley RTC et al.(2015). Assessment of bone mineral density in tenofovir-treated patients with chronic hepatitis B: can the fracture risk assessment tool identify those at greatest risk?. J Infect Dis vol. 211, (3) 374-382.
10.1093/infdis/jiu471
https://qmro.qmul.ac.uk/xmlui/handle/123456789/36431
Berg T, Andreone P, Pol S, Roberts S, Younossi Z, Diago M, Lawitz EJ, Focaccia R et al.(2015). Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study. Liver Int vol. 35, (2) 448-454.
10.1111/liv.12703
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7597
Foster GR(2015). Mutant Ninja viruses. Hepatology vol. 61, (2) 421-423.
10.1002/hep.27540
Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Jablkowski M, Berak H et al.(2015). Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol vol. 62, (2) 294-302.
10.1016/j.jhep.2014.09.013
Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW(2015). High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees?. Epidemiology and Infection vol. 143, (13) 2837-2840.
10.1017/S0950268815000199
Lahiri R, Derwa Y, Bashir Z, Giles E, Torrance HD, Owen HC, O'Dwyer MJ, O'Brien A et al.(2015). Systemic Inflammatory Response Syndrome After Major Abdominal Surgery Predicted by Early Upregulation of TLR4 and TLR5. Ann Surg vol. 2015, (3)
10.5966/sctm.2012-0137
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9508
Marcellin P, Wursthorn K, Wedemeyer H, Chuang W-L, Lau G, Avila C, Peng C-Y, Gane E et al.(2015). Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. J Hepatol vol. 62, (1) 41-47.
10.1016/j.jhep.2014.08.021
Foster GR, De Silva S(2014). Hepatitis C genotype 1. Curr Opin Infect Dis vol. 27, (6) 535-539.
10.1097/QCO.0000000000000112
Potter JL, Hyams C, Shaukat M, Babiker ZO, Macavei VM, Jayasekera N, Kunst H, Foster GR et al. (2014). SHOULD SCREENING FOR CHRONIC VIRAL HEPATITIS IN PATIENTS WITH TUBERCULOSIS BE INTRODUCED TO NICE GUIDELINES?. THORAX. vol. 69, A159-A159.
10.1136/thoraxjnl-2014-206260.318
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7688
Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, Ferguson J, Forton D et al.(2014). Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. Lancet vol. 384, (9958) 1953-1997.
10.1016/S0140-6736(14)61838-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7115
Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster GR(2014). Ethnicity and the diagnosis gap in liver disease: a population-based study. Br J Gen Pract vol. 64, (628) e694-e702.
10.3399/bjgp14X682273
https://qmro.qmul.ac.uk/xmlui/handle/123456789/10805
Buti M, Foster GR, Asselah T(2014). Hepatitis C triple therapy in the near future: New opportunities to cure. JOURNAL OF HEPATOLOGY vol. 61, (5) 1192-1192.
10.1016/j.jhep.2014.01.016
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7016
Foster G, Strasser S, Christensen C, Ma J, Bekele N, Brainard D, Mchutchison J, Chan A et al.(2014). High SVR rates among patients with multiple negative predictive factors across genotypes treated with sofosbuvir-based regimens. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 29, 194-194.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7026
Thompson A, Foster GR, Strasser S, Christensen C, Ma J, Bekele N, Brainard DM, Symonds WT et al.(2014). Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 29, 70-70.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7028
Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A et al.(2014). Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet vol. 384, (9941) 403-413.
10.1016/S0140-6736(14)60494-3
Alazawi W, Mathur R, Abeysekera K, Hull S, Boomla K, Robson J, Foster G(2014). PTU-138 Population-based Study Of Ethnicity And The Diagnosis Gap In Liver Disease. Gut vol. 63 Suppl 1,
10.1136/gutjnl-2014-307263.212
Miller MH, Agarwal K, Austin A, Brown A, Barclay ST, Dundas P, Dusheiko GM, Foster GR et al.(2014). Review article: 2014 UK consensus guidelines - hepatitis C management and direct-acting anti-viral therapy. ALIMENTARY PHARMACOLOGY & THERAPEUTICS vol. 39, (12) 1363-1375.
10.1111/apt.12764
Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski J-P et al.(2014). Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. NEW ENGLAND JOURNAL OF MEDICINE vol. 370, (20) 1889-1898.
10.1056/NEJMoa1402454
Lewis H, Kunkel J, Wilkinson M, Foster GR (2014). A NOVEL NURSE LED MODEL OF TREATMENT DOES NOT INCREASE TREATMENT RATES IN INJECTION DRUG USERS WITH HEPATITIS C VIRUS. JOURNAL OF HEPATOLOGY. vol. 60, S522-S522.
10.1016/S0168-8278(14)61456-2
Mangia A, Marcellin P, Kwo P, Foster GR, Buti M, Braeu N, Muir A, Yang JC et al. (2014). ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY. JOURNAL OF HEPATOLOGY. vol. 60, S523-S524.
10.1016/S0168-8278(14)61459-8
Shoeb D, Dearden J, Weatherall A, Bargery C, Moreea S, Alam S, White E, Vila X et al.(2014). Extended duration therapy with pegylated interferon and ribavirin for patients with genotype 3 hepatitis C and advanced fibrosis: final results from the STEPS trial. J Hepatol vol. 60, (4) 699-705.
10.1016/j.jhep.2013.11.011
Foster GR, Coppola C, Curescu M, Derbala M, Esmat G, Ferenci P, Flisiak R, Lengyel G et al. (2014). IMPACT OF SAFETY-RELATED DOSE REDUCTIONS AND DISCONTINUATIONS (SR-RD) ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA-2a/RIBAVIRIN: RESULTS FROM GUARD-C. JOURNAL OF HEPATOLOGY. vol. 60, S455-S455.
10.1016/S0168-8278(14)61286-1
Martin NK, Devine A, Eaton JW, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ, Legood R et al. (2014). MODELING THE IMPACT OF EARLY ANTIRETROVIRAL THERAPY FOR ADULTS COINFECTED WITH HIV AND HEPATITIS B OR C IN SOUTH AFRICA. JOURNAL OF HEPATOLOGY. vol. 60, S483-S483.
10.1016/S0168-8278(14)61350-7
Zeuzem S, Demasi R, Foster GR, Buti M, Baldini A, Luo D, Witek J, Rizzetto M (2014). PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS. JOURNAL OF HEPATOLOGY. vol. 60, S452-S452.
Gill US, Peppa D, Micco L, Singh HD, Foster GR, Maini MK, Kennedy PTF (2014). SEQUENTIAL NUC THERAPY FOLLOWING PEGYLATED INTERFERON-ALPHA EXPOSURE RESTORES INNATE IMMUNE RESPONSES CONFERRING A TREATMENT ADVANTAGE OVER NUC MONOTHERAPY IN CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 60, S116-S116.
10.1016/S0168-8278(14)60314-7
Foster GR, Strasser S, Christensen C, Ma J, Bekele BN, Brainard DM, Symonds WT, McHutchison JG et al. (2014). SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS. JOURNAL OF HEPATOLOGY. vol. 60, S27-S27.
10.1016/S0168-8278(14)60068-4
Sweeney L, Greenhalgh T, Owiti J, Bhui K, Gomes J, Foster G (2014). UNDERSTANDING OF HEPATITIS B AND C: A QUALITATIVE STUDY WITH IMMIGRANT COMMUNITIES AT INCREASED RISK OF CHRONIC INFECTION. JOURNAL OF HEPATOLOGY. vol. 60, S514-S514.
10.1016/S0168-8278(14)61434-3
Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Riachi G et al. (2014). rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY. JOURNAL OF HEPATOLOGY. vol. 60, S473-S473.
10.1016/S0168-8278(14)61327-1
Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield GM et al.(2014). Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology vol. 146, (2) 430-41.e6.
10.1053/j.gastro.2013.10.058
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo P et al.(2014). Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med vol. 370, (3) 222-232.
10.1056/NEJMoa1306227
Puoti M, Cooper C, Sulkowski MS, Foster GR, Berg T, Villa E, Rodriguez-Perez F, Rustgi V et al. (2014). ABT-450/r/Ombitasvir plus Dasabuvir With or Without Ribavirin in HCV Genotype 1-infected Patients Receiving Stable Opioid Substitution Treatment: Pooled Analysis of Efficacy and Safety in Phase 2 and Phase 3 Trials. HEPATOLOGY. vol. 60, 1135A-1136A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7068
Gill US, Peppa D, Singh HD, Micco L, Foster GR, Maini MK, Kennedy PT (2014). Functional innate immune responses are restored with sequential NUC therapy following Pegylated Interferon-Alpha exposure and not with NUC monotherapy in Chronic Hepatitis B. HEPATOLOGY. vol. 60, 1020A-1021A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7014
Foster GR, De Silva S(2014). Hepatitis C genotype 1. Current Opinion in Infectious Diseases vol. 27, (6) 535-539.
10.1097/QCO.0000000000000112
Hansi NK, Gill US, Banerjee A, Surendraraj N, Patel C, Naik S, Foster GR, Kennedy PT (2014). High levels of Hepatitis B surface antigen (HBsAg) can exclude significant fibrosis and distinguishes true 'immune-tolerance' in children and young adults with Chronic Hepatitis B. HEPATOLOGY. vol. 60, 985A-986A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7139
Martin NK, Devine A, Eaton JW, Miners A, Hallett TB, Foster GR, Dore GJ, Easterbrook PJ et al.(2014). Modeling the impact of early antiretroviral therapy for adults coinfected with HIV and hepatitis B or C in South Africa. AIDS vol. 28 Suppl 1, S35-S46.
10.1097/QAD.0000000000000084
Martin NK, Vickerman P, Dore GJ, Grebely J, Foster GR, Miners A, Hutchinson S, Goldberg DJ et al. (2014). Who should be prioritized for HCV antiviral treatment? A cost-effectiveness analysis including individual and population prevention benefits. HEPATOLOGY. vol. 60, 1042A-1042A.
https://qmro.qmul.ac.uk/xmlui/handle/123456789/7003
Martin NK, Vickerman P, Grebely J, Hellard M, Hutchinson SJ, Lima VD, Foster GR, Dillon JF et al.(2013). Hepatitis C Virus Treatment for Prevention Among People Who Inject Drugs: Modeling Treatment Scale-Up in the Age of Direct-Acting Antivirals. HEPATOLOGY vol. 58, (5) 1598-1609.
10.1002/hep.26431
https://qmro.qmul.ac.uk/xmlui/handle/123456789/18370
Gill US, Patel C, Naik S, Dearden J, Kallis YN, Kooner P, Marley R, Aleong J-AC et al. (2013). Collagen proportionate area but not Ishak fibrosis stage on liver biopsy correlates with age in Chronic Hepatitis B infected young adults. HEPATOLOGY. vol. 58, 427A-428A.
Chen A, Gill US, Ikin CR, Aleong J-AC, Foster GR, Kennedy PT (2013). Differential Hepatitis B virus core nuclear/cytoplasmic staining is a marker of longevity of chronic infection but not disease phase. HEPATOLOGY. vol. 58, 423A-424A.
Kowdley K, Lawitz E, Poordad F, Cohen D, Nelson D, Zeuzem S, Everson G, Kwo P et al. (2013). Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 +/- Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study. AMERICAN JOURNAL OF GASTROENTEROLOGY. vol. 108, S108-S108.
10.14309/00000434-201310001-00364
Gill US, Peppa D, Micco L, Foster GR, Maini MK, Kennedy PT (2013). Sustained restoration of innate immune responses and sAg decline in sequential NUC therapy following failed Pegylated-Interferon-alpha therapy in Chronic Hepatitis B. HEPATOLOGY. vol. 58, 416A-417A.
Zeuzem S, DeMasi R, Foster GR, Buti M, Laeuffer JM, Luo D, Witek J, Rizzetto M (2013). Telaprevir plus peginterferon alfa-2a and ribavirin in treatment-naive patients with genotype 1 HCV and mild to moderate liver disease. HEPATOLOGY. vol. 58, 1129A-1129A.
Agarwal K, Fung SK, Nguyen TT, Cheng W, Sicard E, Ryder SD, Flaherty JF, Lawson E et al. (2013). Twenty Eight Day Safety and Efficacy of Tenofovir Alafenamide (TAF) Fumarate in Chronic Hepatitis B (CHB) Patients. HEPATOLOGY. vol. 58, 675A-675A.
Sali S, Alavian SM, Foster GR, Keyvani H, Mehrnoosh L, Mohammadi N(2013). Influencing factors on the outcome and prognosis of patients with HBV infction: Seven years follow-up. Hepatitis Monthly vol. 13, (7)
10.5812/hepatmon.8743
Lahiri RP, Abeles A, Burnand KM, Alazawi W, Bhattacharya S, Foster GR, Knowles CH(2013). A cross sectional study of colonic diverticulosis in the London Bangladeshi population. United European Gastroenterol J vol. 1, (3) 191-197.
10.1177/2050640613489282
De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin T-I, Dierynck I, Ceulemans H et al.(2013). Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. JOURNAL OF VIRAL HEPATITIS vol. 20, (6) 395-403.
10.1111/jvh.12046
Gill US, Zissimopoulos A, Al-shamma S, Burke K, McPhail M, Barr D, Ross V, Kallis Y et al. (2013). FRAX SCORE IN THE ASSESSMENT OF BONE MINERAL DENSITY CHANGES IN TENOFOVIR TREATED CHRONIC HEPATITIS B PATIENTS. GUT. vol. 62, A190-A190.
10.1136/gutjnl-2013-304907.432
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9836
Foster GR(2013). Reply to: "usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis". J Hepatol vol. 58, (6)
10.1016/j.jhep.2013.01.027
Gill US, Payaniandy L, Schulz J, Payaniandy D, Ross V, Kallis Y, Kooner P, Marley R et al. (2013). SEQUENTIAL ORAL ANTI-VIRAL THERAPY FOLLOWING PEGYLATED-INTERFERON-ALPHA FAILURE SIGNIFICANTLY INCREASES HBSAG DECLINE. GUT. vol. 62, A189-A190.
10.1136/gutjnl-2013-304907.431
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9839
Alazawi W, Heath H, Waters JA, Woodfin A, O'Brien AJ, Scarzello AJ, Ma B, Lopez-Otalora Y et al.(2013). Stat2 loss leads to cytokine-independent, cell-mediated lethality in LPS-induced sepsis. Proc Natl Acad Sci U S A vol. 110, (21) 8656-8661.
10.1073/pnas.1221652110
Lahiri R, Wong J, Waters J, Bhattacharya S, Foster G, Alazawi W (2013). Increased expression of toll-like receptor (TLR) 4 and TLR5 following complex hepato-pancreatico-biliary (HPB) surgery predicts the development of post-operative systemic inflammatory response syndrome (SIRS). BRITISH JOURNAL OF SURGERY. vol. 100, 20-21.
Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR et al.(2013). Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. Journal of Hepatology vol. 58, (5) 883-889.
10.1016/j.jhep.2012.12.023
Lahiri R, Abeles A, Burnand K, Alazawi W, Foster G, Knowles C (2013). The London Bangladeshi community: A population protected against the disease of western civilisation. BRITISH JOURNAL OF SURGERY. vol. 100, 40-40.
Martin NK, Vickerman P, Clements A, Cramp M, De Angeles D, Dillon JF, Fahey S, Foster GR et al. (2013). ARE CURRENT TREATMENT RATES SUFFICIENT TO REDUCE HCV PREVALENCE AMONG PEOPLE WHO INJECT DRUGS? MODEL PROJECTIONS IN SEVEN UK SETTINGS. JOURNAL OF HEPATOLOGY. vol. 58, S356-S356.
10.1016/S0168-8278(13)60869-7
Burger D, Back D, Buggisch P, Buti M, Craxi A, Foster G, Klinker H, Larrey D et al.(2013). Clinical management of drug-drug interactions in HCV therapy: Challenges and solutions. JOURNAL OF HEPATOLOGY vol. 58, (4) 792-800.
10.1016/j.jhep.2012.10.027
Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A et al.(2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis vol. 20, (4)
10.1111/jvh.12020
Alazawi W, Abeysekera K, Dearden J, Glynn M, Kallis Y, Kennedy P, Marley R, Foster GR et al. (2013). IMPLEMENTING EASL & AASLD GUIDELINES FOR HEPATOCELLULAR CARCINOMA SCREENING IS COST-EFFECTIVE IN LONDON'S ETHNICALLY DIVERSE POPULATION. JOURNAL OF HEPATOLOGY. vol. 58, S397-S397.
10.1016/S0168-8278(13)60966-6
Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross VA, Kallis YN, Kooner P, Marley RTC et al. (2013). INDUCTION MAINTENANCE THERAPY IN CHRONIC HEPATITIS B; STEP-DOWN FROM COMBINATION LAMIVUDINE AND TENOFOVIR TO LAMIVUDINE MONOTHERAPY - A POTENTIAL NEW TREATMENT STRATEGY. JOURNAL OF HEPATOLOGY. vol. 58, S302-S302.
10.1016/S0168-8278(13)60748-5
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9891
Alazawi W, Lahiri R, Spyrou A, Giles E, Bashir Z, O'Brien A, Stagg A, Waters J et al. (2013). PATIENTS WITH COMPENSATED CIRRHOSIS HAVE SELECTIVE PARESIS OF FLAGELLIN-INDUCED INNATE IMMUNE RESPONSES DUE TO FAILURES IN ERK SIGNALLING. JOURNAL OF HEPATOLOGY. vol. 58, S133-S134.
10.1016/S0168-8278(13)60321-9
Alazawi W, Abeysekera K, Boomla K, Foster GR (2013). POPULATION BASED STUDY OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) SHOWS DISEASE IS MORE COMMON AMONG BANGLADESHIS IN ETHNICALLY DIVERSE BOROUGHS OF LONDON. JOURNAL OF HEPATOLOGY. vol. 58, S530-S530.
10.1016/S0168-8278(13)61314-8
Foster G, Shoeb D, Weatherall A, Moreea S, Vilar J, Freshwater D, Ryder S, Alexander G et al. (2013). RANDOMISED CONTROLLED TRIAL OF 24 AND 48 WEEKS OF PEGYLATED INTERFERON alfa 2a PLUS RIBAVIRIN IN PATIENTS WITH GENOTYPE 3 HCV AND CIRRHOSIS. JOURNAL OF HEPATOLOGY. vol. 58, S335-S335.
10.1016/S0168-8278(13)60819-3
Marcellin P, Xie Q, Piratvisuth T, Foster GR, Flisiak R, Chen XY, Xie Y, Chen YP et al. (2013). S-Collate COHORT 'REAL-LIFE' STUDY: EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN 1233 PATIENTS WITH CHRONIC HEPATITIS B ACCORDING TO ASIAN AND CAUCASIAN RACE. JOURNAL OF HEPATOLOGY. vol. 58, S18-S18.
10.1016/S0168-8278(13)60043-4
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson D, Zeuzem S, Everson GT, Kwo P et al. (2013). SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333+/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY. JOURNAL OF HEPATOLOGY. vol. 58, S2-S2.
10.1016/S0168-8278(13)60005-7
Kunkel J, Ahmad A, Levi M, Reintjes R, Veldhuijzen I, Foster G, Project H (2013). SCREENING FOR VIRAL HEPATITIS AMONG MIGRANTS IN THE EU - THE QUEST FOR 'GOOD SCREENING PRACTICE'. JOURNAL OF HEPATOLOGY. vol. 58, S400-S401.
10.1016/S0168-8278(13)60974-5
Jacobson I, Dore GJ, Foster GR, Fried MW, Radu M, Rafalskiy VV, Moroz L, Craxi A et al. (2013). SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAIVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL. JOURNAL OF HEPATOLOGY. vol. 58, S574-S574.
10.1016/S0168-8278(13)61424-5
Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Pockros PJ et al.(2013). Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol vol. 58, (3) 488-494.
10.1016/j.jhep.2012.11.013
Foster GR, Zeuzem S, Pianko S, Sarin SK, Piratvisuth T, Shah S, Andreone P, Sood A et al.(2013). Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. Journal of Viral Hepatitis
10.1111/jvh.12020
O'Leary MC, Sarwar M, Hutchinson SJ, Weir A, Schofield J, McLeod A, Cameron S, McTaggart C et al.(2013). The prevalence of hepatitis C virus among people of South Asian origin in Glasgow - Results from a community based survey and laboratory surveillance. TRAVEL MEDICINE AND INFECTIOUS DISEASE vol. 11, (5) 301-309.
10.1016/j.tmaid.2013.08.001
Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson GT, Kwo PY et al.(2012). A 12-Week Interferon-free Treatment Regimen with ABT-450/r, ABT-267, ABT-333 and Ribavirin Achieves SVR12 Rates (Observed Data) of 99% in Treatment-Naive Patients and 93% in Prior Null Responders with HCV Genotype1 Infection. HEPATOLOGY vol. 56, (6) 1515-1516.
Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR, Kautz A et al.(2012). Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement. JOURNAL OF HEPATOLOGY vol. 57, (6) 1379-1390.
10.1016/j.jhep.2012.07.037
Readhead S, Ahmed A, Jenkins H, Nicholls M, Berry P, Shafi S, Foster GR, Ala A (2012). A prospective pilot study of the utility of finger prick dry blood spot testing (DBS) in mosques - a model for chronic viral hepatitis related community screening, health promotion and accessing health care in the UK Pakistani population. HEPATOLOGY. vol. 56, 1095A-1096A.
Pawlotsky J-M, Sarin SK, Foster GR, Peng C-Y, Rasenack J, Flisiak R, Piratvisuth T, Wedemeyer H et al. (2012). Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study. HEPATOLOGY. vol. 56, 309A-310A.
Patel C, Gill U, Alazawi W, Shaw P, Alstead EM, Kallis Y, Kooner P, Marley R et al. (2012). Benchmarking disease activity and progression in Chronic Hepatitis B infected young adults. HEPATOLOGY. vol. 56, 362A-362A.
Cunningham ME, Javaid A, Waters JA, Wright JD, Wong JL, McLauchlan J, Foster GR (2012). Development and validation of a novel capture-fusion model to study primary HCV replication and anti-viral drug sensitivity. HEPATOLOGY. vol. 56, 710A-710A.
Roberts S, Pol S, Andreone P, Younossi Z, Diago M, Lawitz EJ, Focaccia R, Foster GR et al.(2012). Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 27, 177-177.
George PM, Cunningham ME, Galloway-Phillipps N, Badiger R, Alazawi W, Foster GR, Mitchell JA(2012). Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ vol. 2, (4) 501-504.
10.4103/2045-8932.105039
Gill U, Zissimopoulos A, Al-Shamma S, Burke KB, Ross VA, Kallis Y, Kooner P, Marley R et al. (2012). FRAX score in the assessment of Bone Mineral Density changes in Tenofovir treated Chronic Hepatitis B patients: comparison with bone biochemistry and DEXA scanning. HEPATOLOGY. vol. 56, 201A-201A.
Roberts S, Younossi Z, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P et al.(2012). Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY vol. 27, 178-179.
Jacobson IM, Jensen DM, Pol S, Foster GR, Feld JJ, Yoshida EM, Jablkowski MS, Perez-Gomez HR et al. (2012). Safety and efficacy of ritonavir-boosted danoprevir (DNVr), peginterferon alpha-2a (40KD) (P) and ribavirin (R) with or without mericitabine in HCV genotype (G)1-infected treatment-experienced patients with advanced hepatic fibrosis. HEPATOLOGY. vol. 56, 232A-233A.
Alazawi W, Waters JA, Heath H, Woodfin A, O'Brien A, Jacobs M, Goldin R, Nourshargh S et al. (2012). Stat2 loss is associated with enhanced inflammatory cell egress and hepatitis after LPS stimulation despite abolishing inflammatory cytokine production: a novel model of liver inflammation. HEPATOLOGY. vol. 56, 1098A-1099A.
Feld JJ, Jacobson IM, Jensen DM, Foster GR, Pol S, Tam E, Berak H, Vierling JM et al. (2012). Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine (MCB) and ribavirin (R) +/- peginterferon alfa-2a (40KD) (P) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. HEPATOLOGY. vol. 56, 231A-232A.
Kennedy PTF, Sandalova E, Jo J, Gill U, Ushiro-Lumb I, Tan AT, Naik S, Foster GR et al.(2012). Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology vol. 143, (3) 637-645.
10.1053/j.gastro.2012.06.009
https://qmro.qmul.ac.uk/xmlui/handle/123456789/31839
Pianko S, Zeuzem S, Chuang W-L, Foster GR, Sarin SK, Flisiak R, Lee C-M, Andreone P et al.(2012). Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3. JOURNAL OF VIRAL HEPATITIS vol. 19, (9) 623-634.
10.1111/j.1365-2893.2012.01586.x
Lewis H, Cunningham M, Foster G(2012). Second generation direct antivirals and the way to interferon-free regimens in chronic HCV. Best Pract Res Clin Gastroenterol vol. 26, (4) 471-485.
10.1016/j.bpg.2012.09.008
Gill US, Payaniandy L, Schulz J, Ross V, Kallis Y, Kooner P, Marley R, Ushiro-Lumb I et al.(2012). CAN A 3-MONTH "STOPPING RULE" FOR PEGYLATED-INTERFERON-alpha BE APPLIED TO A UK POPULATION OF CHRONIC HEPATITIS B INFECTED PATIENTS OF MIXED GENOTYPE?. GUT vol. 61, A145-A145.
10.1136/gutjnl-2012-302514b.175
https://qmro.qmul.ac.uk/xmlui/handle/123456789/9889
Cunningham ME, Schulz J, Payaniandy L, Kallis Y, Kennedy P, Kooner P, Marley R, Foster GR(2012). EARLY EXPERIENCE WITH TELAPREVIR FOR PATIENTS WITH ADVANCED FIBROSIS OR CIRRHOSIS. GUT vol. 61, A141-A141.
10.1136/gutjnl-2012-302514b.166
Patel C, Gill US, Alazawi W, Shaw P, Alstead E, Kallis Y, Kooner P, Marley R et al.(2012). EVALUATION OF LIVER FIBROSIS IN YOUNG ADULT PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT vol. 61, A133-A133.
10.1136/gutjnl-2012-302514b.148
Lewis H, Wilkinson M, Dalton J, Gardner H, Hothi J, Ibrahim N, King K, Mirza M et al.(2012). EXCELLENT DISEASE FREE AND OVERALL SURVIVAL RATES AFTER LONG TERM FOLLOW-UP OF A COHORT OF INJECTING DRUG USERS TREATED FOR HCV. GUT vol. 61, A134-A135.
10.1136/gutjnl-2012-302514b.151
Alazawi W, Spyrou A, Lahiri R, Waters J, Foster GR(2012). FLAGELLIN-INDUCED IL-6 PRODUCTION IS SELECTIVELY IMPAIRED IN PATIENTS WITH CIRRHOSIS. GUT vol. 61, A130-A130.
10.1136/gutjnl-2012-302514b.141
Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Janmohamed A, Patch D et al.(2012). FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO SUSCEPTIBILITY TO INFECTION IN ALCOHOLIC HEPATITIS. GUT vol. 61, A189-A190.
10.1136/gutjnl-2012-302514c.16a
Gill US, Payaniandy L, Payaniandy D, Schulz J, Ross V, Kallis Y, Kooner P, Marley R et al.(2012). INDUCTION MAINTENANCE TREATMENT IN CHRONIC HEPATITIS B; STEP-DOWN FROM TENOFOVIR AND LAMIVUDINE TO LAMIVUDINE MONOTHERAPY IS EFFECTIVE. GUT vol. 61, A145-A145.
10.1136/gutjnl-2012-302514b.176
Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al.(2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-alpha THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. GUT vol. 61, A145-A146.
10.1136/gutjnl-2012-302514b.177
Lewis H, Reynolds T, Lillis A, Maitland K, Foster GR, Hadley J(2012). MORTALITY AND UTILITY OF PROGNOSTIC SCORING MODELS IN CIRRHOTIC PATIENTS ADMITTED TO A TERTIARY NON-TRANSPLANT INTENSIVE CARE UNIT (ICU) IN THE UK. GUT vol. 61, A99-A200.
10.1136/gutjnl-2012-302514c.39
Khan R, Foster GR, Chowdhury TA(2012). Managing diabetes in patients with chronic liver disease. Postgrad Med vol. 124, (4) 130-137.
10.3810/pgm.2012.07.2574
George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA(2012). Pharmacology and therapeutic potential of interferons. Pharmacol Ther vol. 135, (1) 44-53.
10.1016/j.pharmthera.2012.03.006
Readhead S, Ahmed A, Jenkins H, Nicholls M, Berry P, Foster G, Ala A(2012). THE USE OF DRY BLOOD SPOT TESTING (DBS) FOR VIRAL HEPATITIS IN MOSQUES-A PILOT STUDY OF 3 SURREY CENTRES. GUT vol. 61, A131-A131.
10.1136/gutjnl-2012-302514b.143
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM(2012). Randomized clinical trial: a pilot study investigating the safety and effectiveness of an escalating dose of peginterferon α-2a monotherapy for 48 weeks compared with standard clinical care in patients with hepatitis C cirrhosis. Eur J Gastroenterol Hepatol vol. 24, (5) 543-550.
10.1097/MEG.0b013e3283513e69
Lewis H, Igbe R, Wilkinson M, Dalton J, Gardner H, Hothi J, Ibrahim N, King K et al. (2012). ACTIVE INJECTION DRUG USER'S CAN BE SUCCESSFULLY TREATED FOR HCV AND SIGNIFICANTLY REDUCE ILLICIT DRUG USE POST TREATMENT: REAL LIFE COHORT OF 152 PATIENTS. JOURNAL OF HEPATOLOGY. vol. 56, S446-S446.
10.1016/S0168-8278(12)61143-X
Pawlotsky J-M, Sarin SK, Foster G, Peng C-Y, Rasenack J, Flisiak R, Piratvisuth T, Wedemeyer H et al. (2012). ALISPORIVIR PLUS RIBAVIRIN IS HIGHLY EFFECTIVE AS INTERFERON-FREE OR INTERFERON-ADD-ON REGIMEN IN PREVIOUSLY UNTREATED HCV-GT2 OR GT3 PATIENTS: SVR12 RESULTS FROM VITAL-1 PHASE 2B STUDY. JOURNAL OF HEPATOLOGY. vol. 56, S553-S553.
10.1016/S0168-8278(12)61416-0
Foster GR, Coppola C, Derbala MF, Ferenci P, Orlandini A, Tallarico L, Ahlers S, Tatsch F et al. (2012). BASELINE PREDICTORS FOR SAFETY-RELATED DOSE REDUCTIONS OR TREATMENT DISCONTINUATIONS AMONG PEGINTERFERON ALFA-2A (40KD)/RIBAVIRIN-TREATED PATIENTS AND THEIR IMPACT ON EARLY TREATMENT RESPONSES: GUARD-C INTERIM ANALYSIS. JOURNAL OF HEPATOLOGY. vol. 56, S437-S438.
10.1016/S0168-8278(12)61122-2
Vergis N, Antoniades CG, Zingarelli V, Abeles RD, Ma Y, Shawcross D, Patch D, Rosenberg W et al. (2012). FUNCTIONAL DEFECTS IN CIRCULATING MONOCYTES MAY CONTRIBUTE TO INCREASED SUSCEPTIBILTY TO INFECTION IN ALCOHOLIC HEPATITIS. JOURNAL OF HEPATOLOGY. vol. 56, S43-S43.
10.1016/S0168-8278(12)60113-5
Harris RJ, Ramsay M, Hope VD, Brant L, Hickman M, Foster GR, De Angelis D(2012). Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis. Eur J Public Health vol. 22, (2) 187-192.
10.1093/eurpub/ckr083
Gill US, Papadaki M, Peppa D, Micco L, Li L, Ushiro-Lumb I, Foster GR, Maini MK et al. (2012). MAXIMAL BOOSTING OF INNATE IMMUNITY DURING PEGYLATED INTERFERON-APLHA THERAPY IS REACHED AT 48 WEEKS IN E-ANTIGEN POSITIVE CHRONIC HEPATITIS B. JOURNAL OF HEPATOLOGY. vol. 56, S175-S175.
10.1016/S0168-8278(12)60454-1
Lewis H, Reynolds T, Lillis A, Maitland K, Foster G, Hadley J (2012). MORTALITY AND UTILITY OF PROGNOSTIC SCORING MODELS IN CIRRHOTIC PATIENTS ADMITTED TO A TERTIARY NON-TRANSPLANT INTENSIVE CARE UNIT (ICU) IN THE UK. JOURNAL OF HEPATOLOGY. vol. 56, S251-S251.
10.1016/S0168-8278(12)60646-1
Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, Hezode C, Hirschfield G et al. (2012). TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL. JOURNAL OF HEPATOLOGY. vol. 56, S1-S2.
Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G (2012). WHAT IS THE BEST METHOD OF CASE FINDING FOR CHRONIC VIRAL HEPATITIS IN AT-RISK MIGRANT COMMUNITIES?. JOURNAL OF HEPATOLOGY. vol. 56, S351-S351.
10.1016/S0168-8278(12)60915-5
Cunningham M, Foster GR(2012). Efficacy and safety of telaprevir in patients with genotype 1 hepatitis C infection. Therap Adv Gastroenterol vol. 5, (2) 139-151.
10.1177/1756283X11426895
Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski J-P et al.(2012). The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. HEPATOLOGY vol. 55, (3) 749-758.
10.1002/hep.24744
Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC et al.(2012). UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. ALIMENTARY PHARMACOLOGY & THERAPEUTICS vol. 35, (6) 647-662.
10.1111/j.1365-2036.2012.04992.x
Foster GR, Serfaty LD(2012). Triple combination treatment for chronic hepatitis C with protease inhibitors, pegylated interferon and ribavirin: 'lead-in or no lead-in'?. Liver Int vol. 32 Suppl 1, 61-63.
10.1111/j.1478-3231.2011.02717.x
Konishi H, Okamoto K, Ohmori Y, Yoshino H, Ohmori H, Ashihara M, Hirata Y, Ohta A et al.(2012). An orally available, small-molecule interferon inhibits viral replication. Sci Rep vol. 2,
10.1038/srep00259
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17931
Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M(2012). Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. HEPATOLOGY vol. 55, (1) 49-57.
10.1002/hep.24656
Thompson AJ, Patel K, Chuang W-L, Lawitz EJ, Rodriguez-Torres M, Rustgi VK, Flisiak R, Pianko S et al.(2012). Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. GUT vol. 61, (1) 128-134.
10.1136/gut.2010.236158
Stamataki Z, Qureshi OS, Reynolds GM, Hibbert L, Waters J, Foster GR, Rappoport JZ, Hubscher SG et al. (2011). Lymphocyte interactions with hepatocytes: distinct mechanisms for T and B cells. IMMUNOLOGY. vol. 135, 132-132.
Lewis H, Ibrahim N, Mirza M, Hothi J, Wilkinson M, Foster GR (2011). ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE. HEPATOLOGY. vol. 54, 846A-847A.
Foster GR, Coppola C, Derbala MF, Ferenci P, Orlandini A, Tallarico LG, Ahlers S, Tatsch F et al. (2011). BASELINE PREDICTORS FOR SAFETY-RELATED DOSE REDUCTIONS OR TREATMENT DISCONTINUATIONS AMONG PATIENTS (PTS) TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha) PLUS RIBAVIRIN (RBV) AND THEIR IMPACT ON EARLY TREATMENT RESPONSES: INTERIM ANALYSIS FROM GUARD-C. HEPATOLOGY. vol. 54, 837A-837A.
Gill U, Al-Shamma S, Burke KB, Ross VA, Marley R, Kooner P, Foster GR, Kennedy PT (2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. HEPATOLOGY. vol. 54, 1012A-1012A.
Zeuzem S, Foster GR, Andreone P, Pol S, Lawitz E, Diago M, Roberts SK, Pockros P et al. (2011). DIFFERENT LIKELIHOOD OF ACHIEVING SVR ON A TELAPREVIR-CONTAINING REGIMEN AMONG NULL RESPONDERS, PARTIAL RESPONDERS AND RELAPSERS IRRESPECTIVE OF SIMILAR RESPONSES AFTER A PEGINTERFERON/RIBAVIRIN 4-WEEK LEAD-IN PHASE: REALIZE STUDY SUBANALYSIS. HEPATOLOGY. vol. 54, 986A-987A.
Pol S, Roberts SK, Andreone P, Younossi ZM, Diago M, Lawitz E, Focaccia R, Foster GR et al. (2011). EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE III STUDY. HEPATOLOGY. vol. 54, 374A-375A.
Kennedy PT, Sandalova E, Jo J, Gill U, Li L, Ushiro-Lumb I, Naik S, Foster GR et al. (2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. HEPATOLOGY. vol. 54, 1092A-1093A.
Roberts SK, Andreone P, Pol S, Younossi ZM, Diago M, Lawitz E, Focaccia R, Foster GR et al. (2011). IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY. HEPATOLOGY. vol. 54, 1007A-1008A.
Younossi ZM, Negro F, Serfaty L, Pol S, Diago M, Zeuzem S, Andreone P, Lawitz E et al. (2011). IMPACT OF INSULIN RESISTANCE ON VIROLOGIC RESPONSE TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE REALIZE PHASE III STUDY. HEPATOLOGY. vol. 54, 1008A-1009A.
Pawlotsky JM, Flisiak R, Rasenack J, Sarin SK, Piratvisuth T, Chuang WL, Foster GR, Wedemeyer H et al. (2011). ONCE DAILY ALISPORIVIR INTERFERON (IFN)-FREE REGIMENS ACHIEVE HIGH RATES OF EARLY HCV CLEARANCE IN PREVIOUSLY UNTREATED PATIENTS WITH HCV GENOTYPE (G) 2 OR 3. HEPATOLOGY. vol. 54, 1433A-1433A.
Berg T, Andreone P, Pol S, Roberts SK, Younossi ZM, Diago M, Lawitz E, Focaccia R et al. (2011). PREDICTORS OF VIROLOGIC RESPONSE WITH TELAPREVIR-BASED COMBINATION TREATMENT IN HCV GENOTYPE 1-INFECTED PATIENTS WITH PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: POST-HOC ANALYSIS OF THE PHASE III REALIZE STUDY. HEPATOLOGY. vol. 54, 375A-376A.
Muellhaupt B, Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z et al. (2011). SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. SWISS MEDICAL WEEKLY. vol. 141, 6S-7S.
Mullhaupt B, Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S et al. (2011). SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. SWISS MEDICAL WEEKLY. vol. 141, 18S-18S.
Mullhaupt B, Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al. (2011). Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results. SWISS MEDICAL WEEKLY. vol. 141, 6S-6S.
Lewis H, Ibrahim N, Mirza M, Hothi J, Wilkinson M, Foster G(2011). ACTIVELY INJECTING DRUG USERS CAN BE SUCCESSFULLY TREATED WITH ANTIVIRAL THERAPY FOR HCV, ARE UNLIKELY TO BE RE-INFECTED, AND SIGNIFICANTLY REDUCE THEIR ILLICIT DRUG USE. GUT vol. 60, A9-A10.
10.1136/gutjnl-2011-300857a.21
Gill US, Al-Shamma S, Burke K, Ross V, Marley RTC, Kooner P, Foster GR, Kennedy PTF(2011). BONE MINERAL DENSITY LOSS IN TENOFOVIR TREATED CHRONIC HEPATITIS B VIRUS (HBV) PATIENTS IS A CONSEQUENCE OF VITAMIN D DEFICIENCY AND NOT TENOFOVIR THERAPY. GUT vol. 60, A28-A28.
10.1136/gutjnl-2011-300857a.61
Waters J, Shoeb D, Foster GR(2011). HCV QUASISPECIES ANALYSIS OF PATIENTS WITH GENOTYPE 3 HCV WHO RELAPSE SUGGEST TWO DIFFERENT MECHANISMS OF RELAPSE. GUT vol. 60, A26-A26.
10.1136/gutjnl-2011-300857a.55
Kennedy PTF, Sandalova E, Jo J, Gill US, Li L, Ushiro-Lumb I, Naik S, Foster GR et al.(2011). IMMUNOLOGICAL ANALYSIS AND CLINICAL PROFILE OF CHRONIC HEPATITIS B VIRUS (HBV) INFECTION IN THE YOUNGER PATIENT. GUT vol. 60, A29-A29.
10.1136/gutjnl-2011-300857a.62
Stamataki Z, Qureshi OS, Reynolds GM, Hibbert L, Waters J, Foster GR, Rappoport JZ, Hubscher SG et al.(2011). LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES. GUT vol. 60, A45-A45.
10.1136/gutjnl-2011-300857a.97
Alazawi W, Gamero A, Heath H, Smith P, Jacobs M, Waters J, Foster GR(2011). NF kappa B ACTIVATION BY TLR AGONISTS IS DEFICIENT IN MACROPHAGES LACKING STAT2. GUT vol. 60, A43-A43.
10.1136/gutjnl-2011-300857a.93
Shoeb D, Rowe IA, Freshwater D, Mutimer D, Brown A, Moreea S, Sood R, Marley R et al.(2011). Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol vol. 23, (9) 747-753.
10.1097/MEG.0b013e3283488aba
Foster GR, Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z et al.(2011). SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. GUT vol. 60, A55-A55.
10.1136/gutjnl-2011-300857b.12
Foster G(2011). SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORISATION. GUT vol. 60, A27-A28.
10.1136/gutjnl-2011-300857a.59
Foster G, Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R et al.(2011). TELAPREVIR- BASED THERAPY IN G1 HCV-INFECTED PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN: REALIZE TRIAL FINAL RESULTS. GUT vol. 60, A50-A51.
10.1136/gutjnl-2011-300857b.3
Martin NK, Vickerman P, Foster GR, Miners A, Hutchinson SJ, Goldberg DJ, Hickman M(2011). THE COST-EFFECTIVENESS OF HCV ANTIVIRAL TREATMENT FOR INJECTING DRUG USER POPULATIONS. GUT vol. 60, A25-A25.
10.1136/gutjnl-2011-300857a.53
Foster GR, Hézode C, Bronowicki J-P, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B et al.(2011). Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology vol. 141, (3) 881-889.e1.
10.1053/j.gastro.2011.05.046
Lewis H, Burke K, Begum S, Ushiro-Limb I, Foster G(2011). WHAT IS THE BEST METHOD OF CASE FINDING FOR CHRONIC VIRAL HEPATITIS IN MIGRANT COMMUNITIES?. GUT vol. 60, A26-A26.
10.1136/gutjnl-2011-300857a.56
Shah SR, Patel K, Marcellin P, Foster GR, Manns M, Kottilil S, Healey L, Pulkstenis E et al.(2011). Steatosis Is an Independent Predictor of Relapse Following Rapid Virologic Response in Patients With HCV Genotype 3. CLIN GASTROENTEROL H vol. 9, (8) 688-693.
10.1016/j.cgh.2011.04.029
Patel K, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, Tanwandee T et al.(2011). Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. J GASTROEN HEPATOL vol. 26, (7) 1182-1188.
10.1111/j.1440-1746.2011.06722.x
Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M(2011). Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modeling analysis of its prevention utility. J HEPATOL vol. 54, (6) 1137-1144.
10.1016/j.jhep.2010.08.029
Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z et al.(2011). Telaprevir for retreatment of HCV infection. New England Journal of Medicine vol. 364, (25) 2417-2428.
10.1056/NEJMoa1013086
Patel C, Gill US, Glyn F, Naik S, Foster GR, Kennedy PTF (2011). CHRONIC HBV INFECTION: ASSESSMENT AND MANAGEMENT OF DISEASE IN A YOUNG ADULT CLINIC. GUT. vol. 60,
10.1136/gut.2011.239301.487
Glyn F, Gill US, Alazawi W, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). EFFICACY OF COMBINATION TENOFOVIR PLUS LAMIVUDINE VERSUS TENOFOVIR MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS. GUT. vol. 60, A231-A231.
10.1136/gut.2011.239301.488
Gill US, Al-Shamma S, Burke K, Ross V, Marley R, Kooner P, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. GUT. vol. 60,
10.1136/gut.2011.239301.486
Gill U, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON A MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. GUT. vol. 60, A232-A232.
10.1136/gut.2011.239301.490
Cowan ML, Thomas HC, Foster GR(2011). Therapy for chronic viral hepatitis: current indications, optimal therapies and delivery of care. CLIN MED vol. 11, (2) 184-189.
10.7861/clinmedicine.11-2-184
Gunawan A, Gill US, Glyn F, Kooner P, Marley R, Ushiro-Lumb I, Foster GR, Kennedy PTF (2011). UTILITY OF HBSAG QUANTIFICATION IN DEVELOPING AN INDIVIDUALISED APPROACH TO THE MANAGEMENT OF CHRONIC HEPATITIS B VIRUS IN CLINICAL PRACTICE. GUT. vol. 60,
10.1136/gut.2011.239301.489
Lawitz E, Jacobson I, Godofsky E, Foster GR, Flisiak R, Bennett M, Ryan M, Hinkle J et al. (2011). A PHASE 2B TRIAL COMPARING 24 TO 48 WEEKS TREATMENT WITH TEGOBUVIR (GS-9190)/PEG/RBV TO 48 WEEKS TREATMENT WITH PEG/RBV FOR CHRONIC GENOTYPE 1 HCV INFECTION. JOURNAL OF HEPATOLOGY. vol. 54, S181-S181.
10.1016/S0168-8278(11)60447-9
Gill US, Al-Shamma S, Burke K, Ross V, Kooner P, Marley R, Foster GR, Kennedy PTF (2011). FACTORS DETERMINING BONE MINERAL DENSITY LOSS IN CHRONIC HEPATITIS B PATIENTS: IS TENOFOVIR DISOPROXIL FUMARATE THE MAIN CULPRIT?. JOURNAL OF HEPATOLOGY. vol. 54, S286-S286.
10.1016/S0168-8278(11)60715-0
Foster GR, Buggisch P, Marcellin P, Zeuzem S, Agarwal K, Manns M, Sereni D, Klinker H et al. (2011). FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), +/- RBV +/- PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPE 1A/1B HCV PATIENTS. JOURNAL OF HEPATOLOGY. vol. 54, S172-S172.
10.1016/S0168-8278(11)60427-3
Stamataki Z, Qureshi OS, Reynolds GM, Mee C, Maurel P, Hibbert L, Waters JA, Foster GR et al. (2011). LYMPHOCYTE-HEPATOCYTE INTERACTIONS: HEPATITIS C VIRUS CHANGES THE RULES. JOURNAL OF HEPATOLOGY. vol. 54, S545-S545.
10.1016/S0168-8278(11)61376-7
Gill US, Micco L, Li L, Peppa D, Ushiro-Lumb I, Foster GR, Maini MK, Kennedy PTF (2011). PEGYLATED INTERFERON ALPHA MODULATES INNATE IMMUNITY IN EAG POSITIVE CHRONIC HEPATITIS B AND DETERMINES CHANGES IN HBSAG QUANTIFICATION. JOURNAL OF HEPATOLOGY. vol. 54, S32-S32.
10.1016/S0168-8278(11)60072-X
Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Focaccia R, Younossi ZM et al. (2011). REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN. JOURNAL OF HEPATOLOGY. vol. 54, S3-S3.
10.1016/S0168-8278(11)60007-X
Foster G, Flisiak R, Chuang W-L, George J, Rasenack J, Sood A, Komolmit P, Thongsawat S et al. (2011). RESPIRATORY ALTERATIONS IN GENOTYPE 2/3 CHRONIC HEPATITIS C PATIENTS TREATED WITH PEGYLATED INTERFERON OR ALBINTERFERON-ALFA-2B PLUS RIBAVIRIN IN A RANDOMIZED STUDY. JOURNAL OF HEPATOLOGY. vol. 54, S171-S172.
10.1016/S0168-8278(11)60426-1
Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR et al. (2011). SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER, PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY. JOURNAL OF HEPATOLOGY. vol. 54, S6-S7.
10.1016/S0168-8278(11)60015-9
Foster GR, Zeuzem S, Andreone P, Pol S, Lawitz EJ, Diago M, Roberts S, Pockros PJ et al. (2011). SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION. JOURNAL OF HEPATOLOGY. vol. 54, S3-S4.
10.1016/S0168-8278(11)60008-1
Di Marco V, Capra M, Angelucci E, Borgna-Pignatti C, Telfer P, Harmatz P, Kattamis A, Prossamariti L et al.(2010). Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. BLOOD vol. 116, (16) 2875-2883.
10.1182/blood-2009-11-248724
Javaid A, Hibbert L, Waters JA, Alazawi W, Foster GR (2010). CAN AN EX VIVO HUMAN LIVER BIOPSY MODEL BE USED TO TEST THE EFFICACY OF DRUGS FOR THE TREATMENT OF HEPATITIS C?. HEPATOLOGY. vol. 52, 1217A-1217A.
Martin NK, Vickerman P, Foster GR, Hutchinson S, Goldberg DJ, Hickman M (2010). CAN ANTIVIRAL THERAPY FOR HEPATITIS C REDUCE THE PREVALENCE OF HCV AMONG INJECTING DRUG USER POPULATIONS? A MODELING ANALYSIS OF ITS PREVENTION UTILITY. HEPATOLOGY. vol. 52, 808A-809A.
Zeuzem S, Buggisch P, Agarwal K, Manns MP, Marcellins P, Foster GR, Sereni D, Klinker H et al. (2010). DUAL, TRIPLE, AND QUADRUPLE COMBINATION TREATMENT WITH A PROTEASE INHIBITOR (GS-9256) AND A POLYMERASE INHIBITOR (GS-9190) ALONE AND IN COMBINATION WITH RIBAVIRIN (RBV) OR PEGIFN/RBV FOR UP TO 28 DAYS IN TREATMENT NAiVE, GENOTYPE 1 HCV SUBJECTS. HEPATOLOGY. vol. 52, 400A-401A.
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM (2010). INDIVIDUALIZED CONCENTRATION MONITORED HIGH DOSE RIBAVIRIN IN COMBINATION WITH PEGINTERFERON TO HEPATITIS C GENOTYPE 1 PATIENTS WITH PREVIOUS NONRESPONSE. HEPATOLOGY. vol. 52, 710A-711A.
Tanwar S, Wright M, Foster GR, Ryder SD, Mills PR, Cramp ME, Parkes J, Rosenberg WM (2010). PACIFIC: A PHASE III, RANDOMIZED, MULTICENTER, DOSE ESCALATION, EFFICACY AND SAFETY STUDY EXAMINING THE EFFECTS OF TREATMENT WITH PEGINTERFERON ALFA-2A IN PATIENTS WITH CHILD'S A OR B CIRRHOSIS IN CHRONIC HEPATITIS C VIRUS INFECTION. HEPATOLOGY. vol. 52, 710A-710A.
Foster GR, Shiffman ML, Hadziyanis SJ, Diago M, Nelson DR, Reddy R, Messinger D, Tatsch F (2010). SAFETY AND VIROLOGIC RESPONSE RATES IN PATIENTS WITH HISTORY OF INJECTION DRUG USE (IDU): POOLED ANALYSIS OF DATA FROM FOUR RANDOMIZED PHASE III STUDIES OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN (RBV). HEPATOLOGY. vol. 52, 804A-804A.
Ahmed F, Foster GR(2010). Global hepatitis, migration and its impact on Western healthcare. GUT vol. 59, (8) 1009-1011.
10.1136/gut.2009.206763
Alazawi W, Cunningham M, Dearden J, Foster GR(2010). Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther vol. 32, (3) 344-355.
10.1111/j.1365-2036.2010.04370.x
Uddin G, Shoeb D, Solaiman S, Marley R, Gore C, Ramsay M, Harris R, Ushiro-Lumb I et al.(2010). Prevalence of chronic viral hepatitis in people of south Asian ethnicity living in England: the prevalence cannot necessarily be predicted from the prevalence in the country of origin. J Viral Hepat vol. 17, (5) 327-335.
10.1111/j.1365-2893.2009.01240.x
Alazawi W, Cunningham M, Dearden J, Foster GR (2010). NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW. GUT. vol. 59, A101-A101.
10.1136/gut.2009.208967l
Shoeb D, Rowe I, Brown A, Marley R, Freshwater D, Moreea S, Mutimer D, Foster G (2010). RESPONSE TO ANTIVIRAL THERAPY IN GENOTYPE 3 HEPATITIS C-CIRRHOSIS AND DIABETES BUT NOT ETHNICITY REDUCE RESPONSE RATES. GUT. vol. 59, A76-A77.
10.1136/gut.2009.209072b
Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, Van Baelen B et al. (2010). ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: FINAL RESULTS OF STUDY C209. JOURNAL OF HEPATOLOGY. vol. 52, S27-S27.
10.1016/S0168-8278(10)60059-1
Gane E, Foster GR, Cianciara J, Stedman C, Ryder S, Buti M, Clark E, Tait D (2010). ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND TOLERABILITY OF AZD7295, A NOVEL NS5A INHIBITOR, IN A PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY IN HCV GENOTYPE 1 AND 3 PATIENTS. JOURNAL OF HEPATOLOGY. vol. 52, S464-S464.
10.1016/S0168-8278(10)61194-4
De Meyer S, Ghys A, Foster GR, Beumont-Mauviel M, Van Baelen B, Lin TI, Dierynck I, Picchio G (2010). Analyses of genotype 2/3 HCV variants in patients treated with telaprevir in study C209 showed that the telaprevir resistance profile appears to be consistent across genotypes. ANTIVIRAL THERAPY. vol. 15, A118-A118.
De Meyer S, Foster GR, Ghys A, Beumont M, Van Baelen B, Lin TI, Picchio G (2010). GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF GENOTYPE 2/3 HCV VARIANTS IN PATIENTS TREATED WITH TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN IN STUDY C209. JOURNAL OF HEPATOLOGY. vol. 52, S106-S106.
10.1016/S0168-8278(10)60253-X
Alazawi W, Cunningham M, Dearden J, Foster GR (2010). NATURAL HISTORY OF COMPENSATED CIRRHOSIS DUE TO CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC REVIEW. JOURNAL OF HEPATOLOGY. vol. 52, S402-S402.
10.1016/S0168-8278(10)61039-2
Foster GR(2010). Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Drugs vol. 70, (2) 147-165.
10.2165/11531990-000000000-00000
Thompson A, Diago M, Foster G, Ferenci P, Lurie Y, Stanciu C, Jablkowski M, Haussinger D et al. (2010). RELATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND INSULIN RESISTANCE IN PATIENTS WITH GENOTYPE 1 OR 2/3 CHRONIC HEPATITIS C. JOURNAL OF HEPATOLOGY. vol. 52, S25-S25.
10.1016/S0168-8278(10)60055-4
Foster GR(2009). Recent advances in viral hepatitis. CLIN MED vol. 9, (6) 613-616.
10.7861/clinmedicine.9-6-613
Barakat FM, McDonald V, Foster GR, Tovey MG, Korbel DS(2009). Cryptosporidium parvum infection rapidly induces a protective innate immune response involving type I interferon. J Infect Dis vol. 200, (10) 1548-1555.
10.1086/644601
Alazawi W, Cottle R, Ross V, Ushiro-Lumb I, Alstead EM, Glynn M, Marley R, Foster GR (2009). SUBSTITUTION OF ADEFOVIR FOR TENOFOVIR IN PATIENTS WITH CHRONIC HBV RECEIVING COMBINATION THERAPY WHO HAVE INCOMPLETE CONTROL OR VIROLOGICAL BREAKTHROUGH - IS IT WORTH-WHILE?. HEPATOLOGY. vol. 50, 501A-501A.
Foster GR(2009). Quality of life considerations for patients with chronic hepatitis C. J Viral Hepat vol. 16, (9) 605-611.
10.1111/j.1365-2893.2009.01154.x
Byrne EAL, Katbamna R, Scott C, Coppack SW, Foster GR (2009). PATIENTS WITH M2 ANTIBODIES-WHAT DIAGNOSIS AND FOLLOW-UP ARE THEY GIVEN?. GUT. vol. 58, A68-A68.
Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, Vangeneugden T et al. (2009). ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209. JOURNAL OF HEPATOLOGY. vol. 50, S22-S22.
10.1016/S0168-8278(09)60052-0
Wilkinson M, Crawford V, Tippet A, Jolly F, Turton J, Sims E, Hekker M, Dalton J et al.(2009). Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther vol. 29, (1) 29-37.
10.1111/j.1365-2036.2008.03834.x
Alazawi W, Gamero A, Waters J, Jacobs M, Foster G (2009). STAT2 IS A MAJOR DETERMINANT OF HEPATIC INFLAMMATION AND MORTALITY IN A KNOCKOUT MOUSE MODEL OF PERITONEAL INFLAMMATION. JOURNAL OF HEPATOLOGY. vol. 50, S307-S307.
10.1016/S0168-8278(09)60843-6
Hibbert L, Almazrouee S, Brown A, Barnes E, Foster GR (2009). UPREGULATION OF REGULATORY T CELLS AND REDUCTION OF ANTI-VIRAL IMMUNE RESPONSES TO HEPATITIS C DURING VIRAL ERADICATION IN PATIENTS UNDERGOING ANTIVIRAL TREATMENT. JOURNAL OF HEPATOLOGY. vol. 50, S320-S320.
10.1016/S0168-8278(09)60882-5
Mahtab MA, Rahman S, Karim MF, Khan M, Foster G, Solaiman S, Afroz S(2008). Epidemiology of hepatitis B virus in Bangladeshi general population. HEPATOB PANCREAT DIS vol. 7, (6) 595-600.
Alazawi W, Foster GR(2008). Advances in the diagnosis and treatment of hepatitis B. Curr Opin Infect Dis vol. 21, (5) 508-515.
10.1097/QCO.0b013e32830fb924
Uddin G, Faster GR (2008). TITLE: PREVALENCE OF CHRONIC VIRAL HEPATITIS IN SOUTH ASIANS IMMIGRANTS - PEOPLE FROM PAKISTAN HAVE HIGH RATES OF INFECTION WITH HEPATITIS C AND HIGH RATES OF HEPATITIS C INDUCED CIRRHOSIS IN MIDDLE AGE. HEPATOLOGY. vol. 48, 533A-533A.
Foster GR(2008). Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy?. Addiction vol. 103, (9) 1412-1413.
10.1111/j.1360-0443.2008.02214.x
de Ruiter A, Mercey D, Anderson J, Chakraborty R, Clayden P, Foster G, Gilling-Smith C, Hawkins D et al.(2008). British HIV Association and Children's HIV Association guidelines for the management of HIV infection in pregnant women 2008. HIV MED vol. 9, (7) 452-502.
10.1111/j.1468-1293.2008.00619.x
Foster G, Mathurin P(2008). Hepatitis C virus therapy to date. Antivir Ther vol. 13 Suppl 1, 3-8.
Dakin HA, Foster GR, James ES (2008). Results of a mixed treatment comparison meta-analysis of nucleoside and nucleotide therapies for HBeAG-positive chronic hepatitis B. JOURNAL OF HEPATOLOGY. vol. 48, S256-S256.
10.1016/S0168-8278(08)60689-3
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M(2008). The way forward in HCV treatment - finding the right path (vol 6, pg 991, 2007). NAT REV DRUG DISCOV vol. 7, (1) 83-83.
10.1038/nrd2411
Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR(2007). Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov vol. 6, (12) 975-990.
10.1038/nrd2422
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M(2007). The way forward in HCV treatment - finding the right path. NAT REV DRUG DISCOV vol. 6, (12) 991-1000.
10.1038/nrd2411
Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M(2007). The way forward in HCV treatment--finding the right path. Nat Rev Drug Discov vol. 6, (12) 991-1000.
10.1038/nrd2411
Coyle FM, Taylor NF, Monson JP, Drake WM, Foster GR (2007). Non-alcoholic fatty liver disease is associated with transcriptional dysregulation of the corticosteroid metabolising enzyme II beta HSD-1 leading to excess intrahepatic steroid exposure. HEPATOLOGY. vol. 46, 741A-741A.
Foster GR, Karayiannis P, Lok A, Thomas HC(2007). Editorial. J VIRAL HEPATITIS vol. 14, (9) 599-599.
10.1111/j.1365-2893.2007.00909.x
Brideau-Andersen AD, Huang X, Sun S-CC, Chen TT, Stark D, Sas IJ, Zadik L, Dawes GN et al.(2007). Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases. Proc Natl Acad Sci U S A vol. 104, (20) 8269-8274.
10.1073/pnas.0609001104
Avraamides G, Ng C-Y, David R, Gu Y, Fazekasova H, Mirenda V, Foster GR, Runkel L et al.(2007). IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration. J Interferon Cytokine Res vol. 27, (4) 291-303.
10.1089/jir.2006.0107
Mitchell P, Germain C, Fiori PL, Khamri W, Foster GR, Ghosh S, Lechler RI, Bamford KB et al.(2007). Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun vol. 75, (2) 810-819.
10.1128/IAI.00228-06
Foster GR, Fried MW, Hadziyannis SJ, Messinger D, Freivogel K, Weiland O(2007). Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin. Scand J Gastroenterol vol. 42, (2) 247-255.
10.1080/00365520600955526
Hibbert L, Foster GR (2007). Effects of telapravir (VX950) in a liver biopsy model of HCV infection: Genotype 1 virions are inhibited in vitro but other genotypes are less responsive. JOURNAL OF HEPATOLOGY. vol. 46, S227-S227.
10.1016/S0168-8278(07)62197-7
Hibbert L, Foster GR (2007). Interferon induced gene induction and the anti-viral effects of ifn alpha in liver biopsies with hepatitis C: Viral and host responses determine treatment efficacy. JOURNAL OF HEPATOLOGY. vol. 46, S226-S227.
10.1016/S0168-8278(07)62196-5
Thomas T, Foster G(2007). Nanomedicines in the treatment of chronic hepatitis C - focus on pegylated interferon alpha-2a. INT J NANOMED vol. 2, (1) 19-24.
10.2147/nano.2007.2.1.19
https://qmro.qmul.ac.uk/xmlui/handle/123456789/15683
Wilkinson M, Sims E, Tippett A, Hekker M, Dalton J, Turton J, Jolly F, Crawford V et al. (2007). Therapy for chronic hepatitis C in active injectors: A nurse led clinic allows effective therapy and leads to a reduction in illicit drug use. JOURNAL OF HEPATOLOGY. vol. 46, S204-S205.
10.1016/S0168-8278(07)62136-9
Barton A, Choudhury A, Shanmugasundaram P, McAvinia P, Coyle F, Foster G, Kuitert L (2006). Association between abnormal hepatic enzymes, fatty change in the liver, and acute pulmonary infection in cystic fibrosis. THORAX. vol. 61, II121-II122.
Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F(2006). Genome-wide characterisation of Hepatitis B mutations involved in clinical outcome. HEREDITY vol. 97, (6) 389-397.
10.1038/sj.hdy.6800882
Hollander A, Foster GR, Weiland O(2006). Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis C. Scand J Gastroenterol vol. 41, (5) 577-585.
10.1080/00365520500325952
Jones M, Strang AL, Hibbert L, Smith PL, Jacobs MG, Foster GR (2006). HCVNS5A protein - Functional analysis using a BVDV replicon reporter system shows a correlation between in vitro effects on interferon sensitivity and clinical outcome. JOURNAL OF HEPATOLOGY. vol. 44, S153-S154.
10.1016/S0168-8278(06)80407-1
Szmaragd C, Foster GR, Manica A, Bartholomeusz A, Nichols RA, Balloux F (2006). Hepatitis B virus mutations involved in clinical outcome. JOURNAL OF HEPATOLOGY. vol. 44, S151-S151.
10.1016/S0168-8278(06)80400-9
Swain MG, Foster GR, Hadziyannis SJ, Heathcote EJ, Jensen D, Lee SS, Pockros PJ, Sulkowski M et al. (2006). Poor prognostic factors in heavier patients with chronic hepatitis C (CHC) result in less favourable treatment outcomes. JOURNAL OF HEPATOLOGY. vol. 44, S227-S227.
10.1016/S0168-8278(06)80611-2
Foster GR, Karayiannis P, Thomas HC(2006). Untitled. J VIRAL HEPATITIS vol. 13, (1) 1-1.
10.1111/j.1365-2893.2005.00721.x
Tamir A, Jordan WJ, Ritter M, Habib N, Lechler RI, Foster GR, Lombardi G(2005). Interferon-alpha2a is sufficient for promoting dendritic cell immunogenicity. Clin Exp Immunol vol. 142, (3) 471-480.
10.1111/j.1365-2249.2005.02933.x
Swain MG, Foster G, Hadziyannis S, Heathcote J, Jensen D, Lee S, Pockros P, Sulkowski M et al. (2005). Clustering of poor prognostic factors in heavier patients with chronic hepatitis C (CHC): Baseline characteristics and outcomes with peginterferon alfa-2a (40KD) (PEGASYS (R)) plus ribavirin (RBV, COPEGUS (R)) in randomized, international, Phase III trials. HEPATOLOGY. vol. 42, 687A-688A.
Scott K, Manunta M, Germain C, Smith P, Jones M, Mitchell P, Dessi D, Bamford KB et al.(2005). Qualitatively distinct patterns of cytokines are released by human dendritic cells in response to different pathogens. IMMUNOLOGY vol. 116, (2) 245-254.
10.1111/j.1365-2567.2005.02218.x
D'Souza R, Glynn MJ, Ushiro-Lumb I, Feakins R, Domizio P, Mears L, Alsced E, Kumar P et al.(2005). Prevalence of hepatitis C-related cirrhosis in elderly Asian patients infected in childhood. Clin Gastroenterol Hepatol vol. 3, (9) 910-917.
10.1016/s1542-3565(05)00527-6
D'Souza R, Sabin CA, Foster GR(2005). Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol vol. 100, (7) 1509-1515.
10.1111/j.1572-0241.2005.41403.x
Jones M, Davidson A, Hibbert L, Gruenwald P, Schlaak J, Ball S, Foster GR, Jacobs M(2005). Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. J VIROL vol. 79, (9) 5414-5420.
10.1128/JVI.79.9.5414-5420.2005
Smith PL, Lombardi G, Foster GR(2005). Type I interferons and the innate immune response--more than just antiviral cytokines. Mol Immunol vol. 42, (8) 869-877.
10.1016/j.molimm.2004.11.008
Foster GR(2005). Apoptotic cell death: the caspase-cleavage "gold rush". Lancet vol. 365, (9467) 1293-1294.
10.1016/S0140-6736(05)61009-4
D'Souza R, Sinnott P, Glynn MJ, Sabin CA, Foster GR(2005). An unusual form of autoimmune hepatitis in young Somalian men. Liver Int vol. 25, (2) 325-330.
10.1111/j.1478-3231.2005.01088.x
Swain M, Foster GR, Fried MW, Hadziyannis SJ, Heathcote EJ, Jensen D, Lee SS, Pockros PJ et al. (2005). Clustering of poor prognostic factors in patients with chronic hepatitis C. JOURNAL OF HEPATOLOGY. vol. 42, 222-222.
Weiland O, Fried MW, Hadziyannis S, Messinger D, Freivogel K, Foster GR (2005). Peginterferon alpha-2a (40 kDa) plus ribavirin in treatment-naive patients with chronic hepatitis C and genotype 2 or 3 infection: Individual estimated probability of sustained virological response. JOURNAL OF HEPATOLOGY. vol. 42, 226-227.
D'Souza RFC, Feakins R, Mears L, Sabin CA, Foster GR(2005). Relationship between serum ferritin, hepatic iron staining, diabetes mellitus and fibrosis progression in patients with chronic hepatitis C. Aliment Pharmacol Ther vol. 21, (5) 519-524.
10.1111/j.1365-2036.2005.02382.x
D'Souza R, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C, Foster GR(2005). Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy -- patients' views of early cessation of therapy. Aliment Pharmacol Ther vol. 21, (1) 43-47.
10.1111/j.1365-2036.2004.02295.x
Lim AKP, Taylor-Robinson SD, Patel N, Eckersley RJ, Goldin RD, Hamilton G, Foster GR, Thomas HC et al.(2005). Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut vol. 54, (1) 128-133.
10.1136/gut.2003.030965
FOSTER GR, Feakins R, Kumar P, Alstead E, D'Souza R, Glynn MJ, Mears L, Sabin CA et al.(2005). Natural History of Chronic Hepatitis C Infection: Long Term Follow-up of Asian Patients Infected in Childhood. Clin Gastroenterol Hepatol vol. 3, 910-917.
Foster GR (2004). Novel interferons. ANTIVIRAL THERAPY. vol. 9, H4-H4.
Caronia S, McGarvey MJ, Goldin RD, Foster GR(2004). Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas and HLA antigens. J Viral Hepat vol. 11, (6) 511-518.
10.1111/j.1365-2893.2004.00537.x
Foster GR(2004). Review article: pegylated interferons: chemical and clinical differences. Aliment Pharmacol Ther vol. 20, (8) 825-830.
10.1111/j.1365-2036.2004.02170.x
Jones M, Germain C, Lechler RI, Lombardi G, Foster GR (2004). Immunomodulatory properties of the type I interferons: Type I interferons can both activate and inhibit Th1 activation. HEPATOLOGY. vol. 40, 345A-345A.
Suddle A, Foster G, Powell-Tuck J(2004). The nutritional and metabolic management of hepatic failure in european liver units - a surprising lack of consensus?. CLIN NUTR vol. 23, (5) 953-954.
10.1016/j.clnu.2004.05.001
Pollara G, Jones M, Handley ME, Rajpopat M, Kwan A, Coffin RS, Foster G, Chain B et al.(2004). Herpes simplex virus type-1-induced activation of myeloid dendritic cells: the roles of virus cell interaction and paracrine type IIFN secretion. J IMMUNOL vol. 173, (6) 4108-4119.
10.4049/jimmunol.173.6.4108
Foster G (2004). Best treatment for chronic HCV in 2004. JOURNAL OF VIRAL HEPATITIS. vol. 11, 36-36.
D'Souza RFC, Glynn MJ, Alstead E, Foster GR, Ushiro-Lumb I(2004). Improving hepatitis C services across the UK: response to a walk-in HCV testing service. Gut vol. 53, (9)
10.1136/gut.2004.040212
Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A et al.(2004). Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol vol. 99, (8) 1490-1496.
10.1111/j.1572-0241.2004.30286.x
Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, de Dios C et al.(2004). IFN-alpha subtypes differentially affect human T cell motility. J Immunol vol. 173, (3) 1663-1670.
10.4049/jimmunol.173.3.1663
Foster GR, Masri SH, David R, Jones M, Datta A, Lombardi G, Runkell L, De Dios C et al.(2004). IFN-α subtypes differentially affect human T cell motility. Journal of Immunology vol. 173, (3) 1663-1670.
D'Souza RFC, Glynn MJ, Alstead E, Foster GR, Osonayo C(2004). Improving general practitioners' knowledge of chronic hepatitis C infection. QJM vol. 97, (8) 549-550.
10.1093/qjmed/hch092
D'Souza R, Foster GR(2004). Diagnosis and treatment of chronic hepatitis B. J R Soc Med vol. 97, (7) 318-321.
10.1258/jrsm.97.7.318
D'Souza RFC, Glynn MJ, Alstead E, Osonayo C, Foster GR(2004). Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. QJM vol. 97, (6) 331-336.
10.1093/qjmed/hch060
Reed JR, Vukmanovic-Stejic M, Fletcher JM, Soares MVD, Cook JE, Orteu CH, Jackson SE, Birch KE et al.(2004). Telomere erosion in memory T cells induced by telomerase inhibition at the site of antigenic challenge in vivo. J Exp Med vol. 199, (10) 1433-1443.
10.1084/jem.20040178
https://qmro.qmul.ac.uk/xmlui/handle/123456789/17932
D'Souza R, Foster GR(2004). Diagnosis and treatment of hepatitis C. J R Soc Med vol. 97, (5) 223-225.
10.1258/jrsm.97.5.223
Weiland O, Fried MW, Hadziyannis SJ, Foster GR, Messinger D, Freivogel K, Chaneac M (2004). Combination therapy with peginterferon alfa-2a (40kd) (PEGASYS (R)) plus ribavirin (COPEGUS (R)) in treatment-naive patients with chronic hepatitis C and genotype 1 infection: Individual estimated probability of sustained virological response (SVR). JOURNAL OF HEPATOLOGY. vol. 40, 154-154.
10.1016/S0168-8278(04)90522-3
D'Souza RFC, Glynn MJ, Alstead E, Osonoya C, Foster GR (2004). Knowledge of chronic hepatitis C among East London primary care physicians following the Department of Health's educational campaign. JOURNAL OF HEPATOLOGY. vol. 40, 139-140.
10.1016/S0168-8278(04)90472-2
D'Souza R, Alstead E, Glynn M, Kumar P, Sabin C, Ushiro-Lumb I, Mears L, Feakins R et al. (2004). Natural history of chronic hepatitis C infection: Long term follow up of Asian patients infected in childhood. GUT. vol. 53, A81-A82.
Nkhoma ANS, Macey M, Foster GR (2004). Transition from acute to chronic viral infections - A tissue culture model using respiratory syncitial virus infected cells. GUT. vol. 53, A82-A82.
Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR et al.(2004). Combination therapy with amantadine and interferon in naïve patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol vol. 40, (3) 478-483.
10.1016/j.jhep.2003.11.002
Thomas H, Foster G, Platis D(2004). Mechanisms of action of interferon and nucleoside analogues (vol 39, pg S93, 2003). J HEPATOL vol. 40, (2) 364-364.
10.1016/j.jhep.2003.12.003
Foster GR(2004). Past, present, and future hepatitis C treatments. Semin Liver Dis vol. 24 Suppl 2, 97-104.
10.1055/s-2004-832934
Platis D, Foster GR(2003). Activity of hybrid type I interferons in cells lacking Tyk2: a common region of IFN-alpha 8 induces a response, but IFN-alpha2/8 hybrids can behave like IFN-beta. J Interferon Cytokine Res vol. 23, (11) 655-666.
10.1089/107999003322558791
Foster GR, D'Souza RFC, Main J, Crossey M, Rosenberg W, Murray-Lyon IM, Hayward C (2003). Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - Is it worthwhile?. HEPATOLOGY. vol. 38, 646A-646A.
Platis D, Foster GR(2003). High yield expression, refolding, and characterization of recombinant interferon alpha2/alpha8 hybrids in Escherichia coli. Protein Expr Purif vol. 31, (2) 222-230.
10.1016/s1046-5928(03)00187-6
Foster GR, Fried MW, Hadziyannis SJ, Chaneac M (2003). Treatment of chronic hepatitis C with peginterferon alfa-2a (40KD) (PEGASYS (R)) and ribavirin (COPEGUS (R)): Patient age has a marked influence on the individual estimated probability of achieving a sustained virological response. HEPATOLOGY. vol. 38, 246A-246A.
Judd A, Parry J, Hickman M, McDonald T, Jordan L, Lewis K, Contreras M, Dusheiko G et al.(2003). Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots. J MED VIROL vol. 71, (1) 49-55.
10.1002/jmv.10463
Foster GR(2003). Hepatitis C: an Australian perspective. DRUG-EDUC PREV POLIC vol. 10, (2) 206-207.
Shonde T, Collier J, Lorton A, Lyon IM, Freedman A, Wiselka M, Jack K, Hayward C et al. (2003). Interim results from a multi-centre clinical trial of interferon with ribavirin compared to interferon with ribavirin and amantadine in previously untreated patients with chronic hepatitis C. GUT. vol. 52,
Foster GR(2003). Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opin Pharmacother vol. 4, (5) 685-691.
10.1517/14656566.4.5.685
Waters JA, Jones M, Jacobs M, Roberts P, Karayiannis P, Thomas HC, Foster GR (2003). Effects of interferon on HCV and EMCV replication in the same cell line: Interferon inhibitory NS5A sequences do not inhibit the effects of IFN when expressed in the replicon. JOURNAL OF HEPATOLOGY. vol. 38, 9-9.
10.1016/S0168-8278(03)80440-3
Dick EA, Joarder R, de Jode M, Taylor-Robinson SD, Thomas HC, Foster GR, Gedroyc WMW(2003). MR-guided laser thermal ablation of primary and secondary liver tumours. Clin Radiol vol. 58, (2) 112-120.
10.1053/crad.2002.1129
Foster GR, Tudor-Williams G, White J, Regan L(2003). Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. BJOG vol. 110, (1)
10.1046/j.1471-0528.2003.01036_1.x
Thomas H, Foster G, Platis D (2003). Mechanisms of action of interferon and nucleoside analogues. J Hepatol. vol. 39 Suppl 1, S93-S98.
10.1016/s0168-8278(03)00207-1
Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Sidoli L, Caronia S, Foster GR et al. (2002). Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: Meta-analysis of individual patient data from 6 clinical trials. HEPATOLOGY. vol. 36, 570A-570A.
Jensen CDM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley WGE et al. (2002). Modeling the impact of peginterferon alfa-2a (40KD) (Pegasys (R)) plus ribavirin therapy on life expectancy and medical care costs in chronic hepatitis C. HEPATOLOGY. vol. 36, 603A-603A.
Sebire NJ, Goldin RD, Main J, Foster G(2002). Placental histopathology in maternal hepatitis C virus infection: a morphological and immunohistochemical study. J PATHOL vol. 198, 22A-22A.
Lim AKP, Patel N, Hamilton G, Blomley MJK, Cosgrove DO, Foster GR, Goldin RD, Thomas HC et al.(2002). A prospective assessment of hepatic vein transit times using microbubble-enhanced ultrasound in non-invasive grading of hepatitis C (HCV) related liver disease. GUT vol. 50, A53-A53.
Platis D, Germain C, Lombardi G, Foster G(2002). Immunomodulatory properties of pegylated interferons: The 40 kD pegylated IFN alfa 2a has greater Th1 stimulatory activity than the 12 kD pegylated IFN alfa 2b. J HEPATOL vol. 36, 124-124.
10.1016/S0168-8278(02)80443-3
Lim A, Patel N, Hamilton G, Blomley M, Cosgrove D, Foster G, Goldin R, Thomas H et al.(2002). Non-invasive grading of hepatitis C related liver disease: Microbubble-enhanced ultrasound studies. J HEPATOL vol. 36, 116-116.
10.1016/S0168-8278(02)80412-3
Foster GR(2002). Management of chronic hepatitis C--time for a change?. J Viral Hepat vol. 9, (2) 82-83.
10.1046/j.1365-2893.2002.00334.x
Schulte-Frohlinde E, Seidler B, Burkard I, Freilinger T, Lersch C, Erfle V, Foster GR, Classen M(2002). Different activities of type I interferons on hepatitis B virus core promoter regulated transcription. Cytokine vol. 17, (4) 214-220.
10.1006/cyto.2001.1000
Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD(2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology vol. 35, (2) 433-439.
10.1053/jhep.2002.30688
FOSTER GR(2002). The clinical effectiveness of pegylated interferons in the management of chronic hepatitis C. Aids and Hepatitis Digest vol. 89, 3-5.
Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, Hollanders D et al.(2001). Interferon plus amantadine versus interferon alone in the treatment of naïve patients with chronic hepatitis C: a UK multicentre study. J Hepatol vol. 35, (4) 512-516.
10.1016/s0168-8278(01)00140-4
Forton DM, Allsop JM, Main J, Foster GR, Thomas HC, Taylor-Robinson SD(2001). Evidence for a cerebral effect of the hepatitis C virus. Lancet vol. 358, (9275) 38-39.
10.1016/S0140-6736(00)05270-3
Paterson M, Laxton C, Goldin RD, Ackrill AM, Foster GR(2001). Selection of HCV NS5A quasispecies during IFN therapy in patients with chronic HCV. Dig Dis Sci vol. 46, (7) 1399-1408.
10.1023/a:1010623417345
Forton D, Murphy C, Allsop J, Main J, Foster GR, Thomas HC, Taylor-Robinson SD(2001). Correlation between neuropsychometric scores and cerebral proton magnetic resonance spectroscopy (1H-MRS) in chronic hepatitis C infection. J HEPATOL vol. 34, 160-160.
Leyland M, Torok ME, Acheson J, Foster GR(2000). Hepatitis C virus infection is not associated with a marked increase in the prevalence of ophthalmic morbidity. EYE vol. 14, 889-891.
10.1038/eye.2000.243
Caronia S, Gulati V, McGarvey MJ, Goldin RD, Foster GR(2000). Hepatitis C virus infected hepatocytes and apoptosis. HEPATOLOGY vol. 32, (4) 265A-265A.
Return to top